| Year |
Citation |
Score |
| 2024 |
Remilah AA, Krayim B, Amir E, Tibau A, Robson ME, Abuhadra N, Chen Y, Shepshelovich D, Goldvaser H. The Impact of Previous Therapy on Overall-Survival in Registration Clinical Trials for 1 Line Metastatic Breast Cancer. Critical Reviews in Oncology/Hematology. 104455. PMID 39067779 DOI: 10.1016/j.critrevonc.2024.104455 |
0.366 |
|
| 2024 |
Kappel C, Elliott MJ, Kumar V, Nadler MB, Desnoyers A, Amir E. Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer. Scientific Reports. 14: 3129. PMID 38326452 DOI: 10.1038/s41598-024-53151-8 |
0.323 |
|
| 2024 |
Mittal A, Tamimi F, Molto C, Di Iorio M, Amir E. Benefit of adjuvant bisphosphonates in early breast cancer treated with contemporary systemic therapy: A meta-analysis of randomized control trials. Heliyon. 10: e24793. PMID 38312616 DOI: 10.1016/j.heliyon.2024.e24793 |
0.337 |
|
| 2023 |
Shachar SS, Korzets Y, Shepshelovich D, Zlothover N, Amir E, Tibau A, Goldvaser H. Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review. Cancer Treatment Reviews. 122: 102666. PMID 38064877 DOI: 10.1016/j.ctrv.2023.102666 |
0.34 |
|
| 2023 |
Molto Valiente C, Amir E. Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer. Translational Cancer Research. 12: 1887-1890. PMID 37588734 DOI: 10.21037/tcr-23-365 |
0.313 |
|
| 2022 |
Mittal A, Tamimi F, Molto C, Meti N, Al-Showbaki L, Wilson BE, Amir E. Three-year Disease-free Survival in Randomized Trials of Neoadjuvant Chemotherapy and HER2-targeted therapy in Breast Cancer: A meta-analysis. Critical Reviews in Oncology/Hematology. 103880. PMID 36435297 DOI: 10.1016/j.critrevonc.2022.103880 |
0.326 |
|
| 2021 |
Saleh RR, Nadler MB, Desnoyers A, Meti N, Fazelzad R, Amir E. Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis. Cancer Treatment Reviews. 100: 102283. PMID 34530283 DOI: 10.1016/j.ctrv.2021.102283 |
0.302 |
|
| 2021 |
Ethier JL, Desautels D, Robinson A, Amir E, Kong W, Booth CM. Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer. Jama Oncology. PMID 34236387 DOI: 10.1001/jamaoncol.2021.2140 |
0.332 |
|
| 2021 |
Desnoyers A, Amir E, Tannock IF. Adjuvant Zoledronate Therapy for Women With Breast Cancer-Effective Treatment or Fool's Gold? Jama Oncology. PMID 34165515 DOI: 10.1001/jamaoncol.2021.1516 |
0.479 |
|
| 2021 |
Reinhorn D, Mutai R, Yerushalmi R, Moore A, Amir E, Goldvaser H. Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis. Breast (Edinburgh, Scotland). 58: 173-181. PMID 34158167 DOI: 10.1016/j.breast.2021.05.003 |
0.315 |
|
| 2021 |
Ethier JL, Anderson GM, Austin PC, Clemons M, Parulekar W, Shepherd L, Trasiewicz LS, Tu D, Amir E. Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R. European Journal of Cancer (Oxford, England : 1990). 149: 117-127. PMID 33853037 DOI: 10.1016/j.ejca.2021.02.034 |
0.309 |
|
| 2021 |
Amir E, Cescon DW. Pembrolizumab monotherapy in metastatic triple-negative breast cancer. The Lancet. Oncology. PMID 33676605 DOI: 10.1016/S1470-2045(21)00019-X |
0.301 |
|
| 2021 |
Desnoyers A, Wilson BE, Nadler MB, Amir E. Fragility index of trials supporting approval of anti-cancer drugs in common solid tumours. Cancer Treatment Reviews. 94: 102167. PMID 33652263 DOI: 10.1200/Jco.2020.38.15_Suppl.2055 |
0.381 |
|
| 2020 |
Saleh RR, Meti N, Ribnikar D, Goldvaser H, Ocana A, Templeton AJ, Seruga B, Amir E. Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors. Cancer Medicine. PMID 32886422 DOI: 10.1002/Cam4.3390 |
0.333 |
|
| 2020 |
Desnoyers A, Nadler MB, Kumar V, Saleh R, Amir E. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis. Cancer Treatment Reviews. 90: 102086. PMID 32861975 DOI: 10.1016/J.Ctrv.2020.102086 |
0.432 |
|
| 2020 |
McNamara MG, Jacobs T, Lamarca A, Hubner RA, Valle JW, Amir E. Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. Cancer Treatment Reviews. 89: 102084. PMID 32738738 DOI: 10.1016/J.Ctrv.2020.102084 |
0.315 |
|
| 2020 |
Molto C, Hwang TJ, Borrell M, Andres M, Gich I, Barnadas A, Amir E, Kesselheim AS, Tibau A. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration. Cancer. PMID 32697362 DOI: 10.1002/Cncr.33095 |
0.365 |
|
| 2020 |
Reinhorn D, Yerushalmi R, Moore A, Desnoyers A, Saleh RR, Amir E, Goldvaser H. Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer. Breast Cancer Research and Treatment. 182: 259-266. PMID 32488391 DOI: 10.1007/S10549-020-05715-1 |
0.414 |
|
| 2020 |
Keilty D, Namini SN, Swain M, Maganti M, Cil TD, McCready DR, Cescon DW, Amir E, Fleming R, Mulligan AM, Fyles A, Croke JM, Liu FF, Levin W, Koch CA, et al. Patterns of recurrence and predictors of survival in breast cancer patients treated with neoadjuvant chemotherapy, surgery, and radiation. International Journal of Radiation Oncology, Biology, Physics. PMID 32407932 DOI: 10.1016/J.Ijrobp.2020.04.044 |
0.397 |
|
| 2020 |
Templeton AJ, Amir E, Tannock IF. Informative censoring - a neglected cause of bias in oncology trials. Nature Reviews. Clinical Oncology. PMID 32273582 DOI: 10.1038/S41571-020-0368-0 |
0.488 |
|
| 2020 |
Lambert J, Lamacie M, Thampinathan B, Altaha MA, Esmaeilzadeh M, Nolan M, Fresno CU, Somerset E, Amir E, Marwick TH, Wintersperger BJ, Thavendiranathan P. Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity. Heart (British Cardiac Society). PMID 32098808 DOI: 10.1136/Heartjnl-2019-316297 |
0.304 |
|
| 2020 |
Calvillo-Argüelles O, Abdel-Qadir H, Suntheralingam S, Michalowska M, Amir E, Thavendiranathan P. Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer. The American Journal of Cardiology. PMID 32087998 DOI: 10.1016/J.Amjcard.2020.01.029 |
0.408 |
|
| 2020 |
Ocaña A, Amir E, Pandiella A. HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates. Breast Cancer Research : Bcr. 22: 15. PMID 32005279 DOI: 10.1186/S13058-020-1252-7 |
0.356 |
|
| 2020 |
Saleh R, Bedard PL, Nguyen P, Malone ER, Yu C, Amir E, Earle C, Gyawali B, Hansen AR, Mittmann N, Peng Y, Pugh TJ, Abdul Razak AR, Sabatini P, Spreafico A, et al. An evaluation of administrative data linkage for measurement of real-world outcomes of large clinical panel sequencing for advanced solid tumors. Journal of Clinical Oncology. 38: e19303-e19303. DOI: 10.1200/Jco.2020.38.15_Suppl.E19303 |
0.374 |
|
| 2020 |
Almugbel F, Al-Showbaki L, Nadler M, Desnoyers A, Saleh R, Amir E. Macrocytosis as a predictor of response to capecitabine in solid cancers: A meta-analysis. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E13080 |
0.411 |
|
| 2020 |
Desnoyers A, Nadler M, Kumar V, Saleh R, Amir E. Comparison of treatment-related adverse events (TRAE) of different CDK4/6 inhibitors (CDK4/6i) in metastatic breast cancer (MBC): A network meta-analysis. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E13052 |
0.385 |
|
| 2020 |
Rodríguez AB, Molto C, Hwang TJ, Vokinger KN, Tapia JC, Saladich IJG, Templeton AJ, Barnadas A, Amir E, Tibau A. Factors associated with change in the magnitude of clinical benefit of anti-cancer drugs in the post-marketing period. Journal of Clinical Oncology. 38: 7052-7052. DOI: 10.1200/Jco.2020.38.15_Suppl.7052 |
0.357 |
|
| 2020 |
Nadler M, Desnoyers A, Saleh R, Amir E. Post-hoc power of clinical trials supporting anticancer drug approval by FDA. Journal of Clinical Oncology. 38: 2018-2018. DOI: 10.1200/Jco.2020.38.15_Suppl.2018 |
0.334 |
|
| 2020 |
Desnoyers A, Nadler MB, Saleh R, Amir E. Abstract P4-15-01: Fragility index of trials supporting approval of breast cancer drugs Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P4-15-01 |
0.435 |
|
| 2020 |
Saleh R, Nadler MB, Desnoyers A, Fazelzad R, Amir E. Abstract P4-14-09: Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P4-14-09 |
0.411 |
|
| 2020 |
Almugbel FA, Saleh R, Ocana A, Pandiella A, Amir E. Abstract P4-10-11: PIK3CA status as a predictor of benefit from drugs targeting the PI3K/AKT/mTOR pathway: A meta-analysis of randomized trials Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P4-10-11 |
0.32 |
|
| 2020 |
Tai F, Croxford R, Austin P, Amir E, Argüelles OC, Ross HJ, Lee D, Thavendiranathan P, Abdel-Qadir H. Prognosis Of Heart Failure Following Cardiotoxic Breast Cancer Chemotherapy: A Retrospective Matched Cohort Study Journal of the American College of Cardiology. 75: 708. DOI: 10.1016/S0735-1097(20)31335-8 |
0.393 |
|
| 2020 |
Bobrowski D, Zhou L, Austin P, Arguelles OC, Amir E, Lee D, Thavendiranathan P, Abdel-Qadir H. Statins Are Associated With Lower Risk Of Heart Failure After Anthracycline And Trastuzumab Chemotherapy For Early Stage Breast Cancer Journal of the American College of Cardiology. 75: 7. DOI: 10.1016/S0735-1097(20)30553-2 |
0.416 |
|
| 2019 |
Bobrowski D, Suntheralingam S, Calvillo-Argüelles O, Michalowska M, Amir E, Sacha Bhatia R, Thavendiranathan P, Abdel-Qadir H. The Yield of Routine Cardiac Imaging in Breast Cancer Patients Receiving Trastuzumab-based Treatment: A Retrospective Cohort Study. The Canadian Journal of Cardiology. PMID 32621888 DOI: 10.1016/J.Cjca.2019.12.021 |
0.391 |
|
| 2019 |
Tran B, Ruiz-Morales JM, Gonzalez-Billalabeitia E, Patrikidou A, Amir E, Seidel C, Bokemeyer C, Fankhauser C, Hermanns T, Rumyantsev A, Tryakin A, Brito M, Fléchon A, Kwan EM, Cheng T, et al. Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3). Cancer Medicine. PMID 31715650 DOI: 10.1002/Cam4.2674 |
0.332 |
|
| 2019 |
Tau N, Shochat T, Gafter-Gvili A, Amir E, Shepshelovich D. Undisclosed Financial Conflicts of Interest of Authors of Clinical Drug Trials Published in Influential Medical Journals: A Cohort Study. Mayo Clinic Proceedings. 94: 2272-2276. PMID 31685153 DOI: 10.1016/J.Mayocp.2019.08.025 |
0.307 |
|
| 2019 |
Saleh RR, Peinado P, Fuentes-Antrás J, Pérez-Segura P, Pandiella A, Amir E, Ocaña A. Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis. Frontiers in Oncology. 9: 1040. PMID 31681578 DOI: 10.3389/Fonc.2019.01040 |
0.392 |
|
| 2019 |
Noblejas-López MDM, Nieto-Jiménez C, Morcillo García S, Pérez-Peña J, Nuncia-Cantarero M, Andrés-Pretel F, Galán-Moya EM, Amir E, Pandiella A, Győrffy B, Ocana A. Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome. Oncoimmunology. 8: e1629780. PMID 31646075 DOI: 10.1093/Annonc/Mdz253.090 |
0.343 |
|
| 2019 |
McNamara MG, Amir E. Response to letter to the editor: The impact of the nodal status and resection margin on the effectiveness of adjuvant chemotherapy for pancreatic cancer: It calls for more careful evaluation. Journal of Surgical Oncology. PMID 31471897 DOI: 10.1002/Jso.25691 |
0.339 |
|
| 2019 |
Shepshelovich D, Yahav D, Tibau A, Amir E. Assessment of frequency and reporting of design changes among clinical drug trials published in influential medical journals. European Journal of Internal Medicine. PMID 31439377 DOI: 10.1016/J.Ejim.2019.08.009 |
0.334 |
|
| 2019 |
Chia S, Bedard PL, Hilton J, Amir E, Gelmon K, Goodwin R, Villa D, Cabanero M, Tu D, Tsao M, Seymour L. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229). The Oncologist. PMID 31420468 DOI: 10.1634/Theoncologist.2019-0321 |
0.417 |
|
| 2019 |
Goldvaser H, Korzets Y, Shepshelovich D, Yerushalmi R, Sarfaty M, Ribnikar D, Thavendiranathan P, Amir E. Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis. Jnci Cancer Spectrum. 3: pkz033. PMID 31360906 DOI: 10.1093/Jncics/Pkz033 |
0.414 |
|
| 2019 |
Abdel-Qadir H, Thavendiranathan P, Austin PC, Lee DS, Amir E, Tu JV, Fung K, Anderson GM. Development and validation of a multivariable prediction model for major adverse cardiovascular events after early stage breast cancer: a population-based cohort study. European Heart Journal. PMID 31318428 DOI: 10.1093/Eurheartj/Ehz460 |
0.368 |
|
| 2019 |
Rodríguez-Fernández IA, Rodríguez-Romo L, Hernandez-Barajas D, Gonzalez-Conchas GA, Verdines-Perez A, Templeton AJ, Ocana A, Seruga B, Tannock IF, Amir E, Vera-Badillo FE. Adjuvant Radiation Therapy After Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-analysis. European Urology Oncology. 2: 448-455. PMID 31277782 DOI: 10.1016/J.Euo.2018.10.003 |
0.46 |
|
| 2019 |
Srikanthan A, Amir E, Gupta A, Baxter N, Kennedy ED. Assisting with Decision-Making: How Standardized Information Impacts Breast Cancer Patient Decisions Regarding Fertility Trade-Offs and Chemotherapy. Journal of Adolescent and Young Adult Oncology. PMID 31241397 DOI: 10.1089/Jayao.2019.0027 |
0.37 |
|
| 2019 |
Saleh RR, Antrás JF, Peinado P, Pérez-Segura P, Pandiella A, Amir E, Ocaña A. Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis. Cancer Treatment Reviews. 77: 11-19. PMID 31174180 DOI: 10.1016/J.Ctrv.2019.05.006 |
0.337 |
|
| 2019 |
Srikanthan A, Ethier JL, Amir E. The Voices of Young Women with Breast Cancer: Providing Support and Information for Improved Fertility Preservation Discussions. Journal of Adolescent and Young Adult Oncology. PMID 31158039 DOI: 10.1089/Jayao.2019.0030 |
0.374 |
|
| 2019 |
Ghate K, Amir E, Kuksis M, Hernandez-Barajas D, Rodriguez-Romo L, Booth CM, Vera-Badillo FE. PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis. Cancer Treatment Reviews. 76: 51-56. PMID 31125908 DOI: 10.1016/J.Ctrv.2019.05.002 |
0.301 |
|
| 2019 |
Goldvaser H, Amir E. Role of Bisphosphonates in Breast Cancer Therapy. Current Treatment Options in Oncology. 20: 26. PMID 30874905 DOI: 10.1007/s11864-019-0623-8 |
0.338 |
|
| 2019 |
Amir E. Endpoint selection in HER2-positive early breast cancer. The Lancet. Oncology. PMID 30709632 DOI: 10.1016/S1470-2045(18)30779-4 |
0.397 |
|
| 2019 |
Feng S, Cao Y, Amir E, Chen EX. Evaluating the value of checkpoint inhibitor therapy using the ASCO and ESMO frameworks. Journal of Clinical Oncology. 37: 17-17. DOI: 10.1200/Jco.2019.37.8_Suppl.17 |
0.363 |
|
| 2019 |
Al-Ezzi EM, Riromar JJA, Amir E, Fazelzad R, Hansen AR. Cross-trial comparison of taxane versus non-taxane combination chemotherapy regimens for advanced penile cancer (APC): A systematic review. Journal of Clinical Oncology. 37: 511-511. DOI: 10.1200/Jco.2019.37.7_Suppl.511 |
0.393 |
|
| 2019 |
Nadler M, Saleh R, Desnoyers A, Amir E. The efficacy and safety of exercise in metastatic solid cancer: A meta-analysis of randomized control trials. Journal of Clinical Oncology. 37: e23107-e23107. DOI: 10.1200/Jco.2019.37.15_Suppl.E23107 |
0.34 |
|
| 2019 |
Desnoyers A, Saleh R, Nadler M, Amir E. Associations with response to poly (ADP-ribose) polymerase (PARP) inhibitors in metastatic breast cancer: Results of a meta-regression analysis. Journal of Clinical Oncology. 37: e12567-e12567. DOI: 10.1200/Jco.2019.37.15_Suppl.E12567 |
0.434 |
|
| 2019 |
Feng S, Cao Y, Amir E, Chen EX. Evaluating the American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) value frameworks for Food and Drug Administration (FDA) approved checkpoint inhibitors (CIs). Journal of Clinical Oncology. 37: 6624-6624. DOI: 10.1200/Jco.2019.37.15_Suppl.6624 |
0.374 |
|
| 2019 |
Molto C, Hwang TJ, Andres M, Borrell M, Gich Saladich IJ, Barnadas A, Amir E, Kesselheim AS, Tibau Martorell A. Clinical benefit of breakthrough cancer drugs approved by the United States Food and Drug Administration. Journal of Clinical Oncology. 37: 6513-6513. DOI: 10.1200/Jco.2019.37.15_Suppl.6513 |
0.414 |
|
| 2019 |
Goldvaser H, Yasmin KC, Shepshelovich D, Yerushalmi R, Sarfaty M, Ribnikar D, Thavendiranathan P, Amir E. De-escalating adjuvant trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A systemic review and meta-analysis. Journal of Clinical Oncology. 37: 524-524. DOI: 10.1200/Jco.2019.37.15_Suppl.524 |
0.424 |
|
| 2019 |
Lohmann AE, Soldera SV, Pimentel I, Ribnikar D, Ennis M, Amir E, Goodwin PJ. Association of obesity with breast cancer outcome in relation to cancer subtypes. Journal of Clinical Oncology. 37: 11557-11557. DOI: 10.1200/Jco.2019.37.15_Suppl.11557 |
0.383 |
|
| 2019 |
Tan TJY, Cescon DW, Wang L, Amir E, Vieira D, Zammit K, Warr D, Elser C, Butler MO, Abdul Razak AR, Hansen AR, Spreafico A, Siu LL, Bedard PL. Hyperprogressive disease in advanced triple-negative breast cancer (aTNBC) treated with immunotherapy (IO). Journal of Clinical Oncology. 37: 1086-1086. DOI: 10.1200/Jco.2019.37.15_Suppl.1086 |
0.432 |
|
| 2019 |
Ethier J, Parulekar W, Shepherd L, Summers L, Strasser-Weippl K, Tu D, Amir E. Abstract P4-14-03: Influence of competing risks of death on the interpretation of adjuvant endocrine therapy trials for breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P4-14-03 |
0.437 |
|
| 2019 |
Rodríguez AB, Tapia JC, Hwang T, Valiente CM, Templeton AJ, Barnadas A, Amir E, Tibau A. Change in magnitude of clinical benefit, overall survival (OS) and quality of life (QoL) between time of approval and post-marketing among cancer drugs approved by the US Food and Drug Administration (FDA) 2006-2015 Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz263.001 |
0.392 |
|
| 2019 |
McNamara MG, Jacobs T, Frizziero M, Pihlak R, Lamarca A, Hubner RA, Valle JW, Amir E. Prognostic and predictive impact of high tumor mutation burden (TMB) in solid tumors: A systematic review and meta-analysis Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz239 |
0.35 |
|
| 2019 |
Puts M, Strohschein F, Mclean B, Alqurini N, Syed AT, Amir E, Béland F, Berger A, Bergman S, Vanderbyl B, Breunis H, Elser C, Emmenegger U, Fung S, Hsu T, et al. Clinical And Cost-Effectiveness Of Comprehensive Geriatric Assessment And Management For Canadian Elders With Cancer: The 5C Study – Initial Recruitment And Implementation Results Journal of Geriatric Oncology. 10. DOI: 10.1016/S1879-4068(19)31271-8 |
0.32 |
|
| 2019 |
Nolan MT, Selam MA, Amir E, Koch A, Yip P, Michalowska M, Wintersperger B, Thavendiranathan P. CARDIOTOXICITY PHENOTYPES IN WOMEN TREATED WITH ANTHRACYCLINES AND TRASTUZUMAB FOR EARLY STAGE BREAST CANCER Journal of the American College of Cardiology. 73: 799. DOI: 10.1016/S0735-1097(19)31406-8 |
0.385 |
|
| 2019 |
Keilty D, Namini SN, Swain M, Maganti M, Cil T, McCready D, Cescon D, Amir E, Fleming R, Mulligan A, Levin W, Liu F, Croke J, Fyles A, Koch C, et al. Predictors of Survival and Patterns of Recurrence in Breast Cancer Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation International Journal of Radiation Oncology*Biology*Physics. 105: E24-E25. DOI: 10.1016/J.Ijrobp.2019.06.671 |
0.377 |
|
| 2018 |
Molto Valiente C, Borrell M, Hwang T, Gich Saladich I, Barnadas A, Amir E, Kesselheim A, Tibau A. Magnitude of clinical benefit of trials supporting US Food and Drug Administration (FDA) approval of breakthrough and non-breakthrough drugs. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii564-viii565. PMID 32137486 DOI: 10.1093/Annonc/Mdy297.008 |
0.302 |
|
| 2018 |
Borrell Puy M, Molto Valiente C, Vokinger K, Hwang T, Ocana Fernandez A, Templeton AJ, Seruga B, Gich Saladich I, Barnadas A, Amir E, Tibau A. Magnitude of clinical benefit in trials supporting US Food and Drug Administration (FDA) accelerated approval (AA) and European Medicines Agency (EMA) conditional marketing authorisation (CMA) and subsequent trials supporting conversion to full approval. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii564. PMID 32137485 DOI: 10.1093/Annonc/Mdy297.007 |
0.318 |
|
| 2018 |
Shepshelovich D, Tibau A, Molto C, Goldvaser H, Ocana A, Šeruga B, Amir E. Assessment of Frequency and Reporting of Changes in Cancer Trial Design After Initiation of Patient Accrual. Jama Oncology. PMID 30520936 DOI: 10.1001/Jamaoncol.2018.5877 |
0.386 |
|
| 2018 |
Kitchlu A, McArthur E, Amir E, Booth CM, Sutradhar R, Majeed H, Nash DM, Silver SA, Garg AX, Chan CT, Kim SJ, Wald R. Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study. Journal of the National Cancer Institute. PMID 30423160 DOI: 10.1093/Jnci/Djy167 |
0.337 |
|
| 2018 |
Goldvaser H, Ribnikar D, Majeed H, Ocaña A, Amir E. Absolute benefit from adjuvant chemotherapy in contemporary clinical trials: A systemic review and meta-analysis. Cancer Treatment Reviews. 71: 68-75. PMID 30366201 DOI: 10.1016/J.Ctrv.2018.10.010 |
0.418 |
|
| 2018 |
Liu S, Aghel N, Belford L, Silversides CK, Nolan M, Amir E, Maxwell C, Thavendiranathan P. Cardiac Outcomes in Pregnant Women With Treated Cancer. Journal of the American College of Cardiology. 72: 2087-2089. PMID 30336834 DOI: 10.1016/J.Jacc.2018.07.085 |
0.362 |
|
| 2018 |
Tibau A, Molto C, Borrell M, Del Paggio JC, Barnadas A, Booth CM, Amir E. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials. Jama Oncology. PMID 30267037 DOI: 10.1001/Jamaoncol.2018.4300 |
0.361 |
|
| 2018 |
Pérez-Peña J, Győrffy B, Amir E, Pandiella A, Ocaña A. Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer. Breast Cancer Research and Treatment. PMID 30206781 DOI: 10.1007/S10549-018-4965-X |
0.315 |
|
| 2018 |
Algorashi I, Goldvaser H, Ribnikar D, Cescon DW, Amir E. Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy. Cancer Treatment Reviews. 70: 138-143. PMID 30176513 DOI: 10.1016/J.Ctrv.2018.08.009 |
0.432 |
|
| 2018 |
Ocaña A, Amir E, Pandiella A. Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results. Oncotarget. 9: 31915-31919. PMID 30159132 DOI: 10.18632/Oncotarget.25739 |
0.438 |
|
| 2018 |
Shepshelovich D, Amir E. Expedited approval of cancer drugs without randomized controlled trials: Too good to be true? Oncotarget. 9: 30942-30943. PMID 30123417 DOI: 10.18632/Oncotarget.25799 |
0.39 |
|
| 2018 |
Lohmann AE, Dowling RJO, Ennis M, Amir E, Elser C, Brezden-Masley C, Vandenberg T, Lee E, Fazaee K, Stambolic V, Goodwin PJ, Chang MC. Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer. Jnci Cancer Spectrum. 2: pky028. PMID 30035251 DOI: 10.1093/Jncics/Pky028 |
0.373 |
|
| 2018 |
Kitchlu A, Shapiro J, Amir E, Garg AX, Kim SJ, Wald R, Harel Z. Representation of Patients With Chronic Kidney Disease in Trials of Cancer Therapy. Jama. 319: 2437-2439. PMID 29922818 DOI: 10.1001/Jama.2018.7260 |
0.363 |
|
| 2018 |
Majeed H, Amir E. Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancer. Journal of Thoracic Disease. 10: S995-S998. PMID 29849197 DOI: 10.21037/Jtd.2018.03.153 |
0.35 |
|
| 2018 |
Salah S, Lewin J, Amir E, Abdul Razak A. Tumor necrosis and clinical outcomes following neoadjuvant therapy in soft tissue sarcoma: A systematic review and meta-analysis. Cancer Treatment Reviews. 69: 1-10. PMID 29843049 DOI: 10.1016/J.Ctrv.2018.05.007 |
0.306 |
|
| 2018 |
Thavendiranathan P, Abdel-Qadir H, Fischer HD, Liu Y, Camacho X, Amir E, Austin PC, Lee DS. Risk-Imaging Mismatch in Cardiac Imaging Practices for Women Receiving Systemic Therapy for Early-Stage Breast Cancer: A Population-Based Cohort Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018779736. PMID 29791284 DOI: 10.1200/Jco.2018.77.9736 |
0.33 |
|
| 2018 |
Templeton AJ, Rodríguez-Lescure Á, Ruíz A, Alba E, Calvo L, Ruíz-Borrego M, Santaballa A, Rodríguez CA, Crespo C, Ramos M, Gracia-Marco JM, Lluch A, Álvarez I, Casas MI, Sánchez-Aragó M, ... ... Amir E, et al. Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy. Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. PMID 29766456 DOI: 10.1007/S12094-018-1885-5 |
0.422 |
|
| 2018 |
Shepshelovich D, Tibau A, Goldvaser H, Molto C, Ocana A, Seruga B, Amir E. Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017775593. PMID 29641296 DOI: 10.1200/Jco.2017.77.5593 |
0.345 |
|
| 2018 |
Tibau A, Anguera G, Andrés-Pretel F, Templeton AJ, Seruga B, Barnadas A, Amir E, Ocana A. Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer. Oncotarget. 9: 15061-15067. PMID 29599926 DOI: 10.18632/Oncotarget.24589 |
0.421 |
|
| 2018 |
Martínez-Canales S, López de Rodas M, Nuncia-Cantarero M, Páez R, Amir E, Győrffy B, Pandiella A, Galán-Moya EM, Ocaña A. Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer. Cancer Medicine. PMID 29575713 DOI: 10.1002/Cam4.1406 |
0.333 |
|
| 2018 |
Ethier JL, Ocaña A, Rodríguez Lescure A, Ruíz A, Alba E, Calvo L, Ruíz-Borrego M, Santaballa A, Rodríguez CA, Crespo C, Ramos M, Gracia Marco J, Lluch A, Álvarez I, Casas M, ... ... Amir E, et al. Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study. European Journal of Cancer (Oxford, England : 1990). 94: 199-205. PMID 29573665 DOI: 10.1016/J.Ejca.2018.02.018 |
0.39 |
|
| 2018 |
Majeed H, Amir E. EQUATOR-Oncology: reducing the latitude of cancer trial design and reporting. British Journal of Cancer. PMID 29471307 DOI: 10.1038/Bjc.2017.427 |
0.342 |
|
| 2018 |
Goldvaser H, Majeed H, Ribnikar D, Šeruga B, Ocaña A, Cescon DW, Amir E. Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis. Breast Cancer Research and Treatment. PMID 29423899 DOI: 10.1007/S10549-018-4710-5 |
0.452 |
|
| 2018 |
Barua R, Templeton AJ, Seruga B, Ocana A, Amir E, Ethier JL. Hyperglycaemia and Survival in Solid Tumours: A Systematic Review and Meta-analysis. Clinical Oncology (Royal College of Radiologists (Great Britain)). PMID 29395413 DOI: 10.1200/Jco.2017.35.15_Suppl.E18158 |
0.343 |
|
| 2018 |
Srikanthan A, Amir E, Bedard P, Giuliani M, Hodgson D, Laframboise S, Prica A, Yee K, Greenblatt E, Lewin J, Gupta A. Fertility preservation in post-pubescent female cancer patients: A practical guideline for clinicians. Molecular and Clinical Oncology. 8: 153-158. PMID 29387409 DOI: 10.3892/Mco.2017.1486 |
0.373 |
|
| 2018 |
Lega IC, Austin PC, Fischer HD, Fung K, Krzyzanowska MK, Amir E, Lipscombe LL. The Impact of Diabetes on Breast Cancer Treatments and Outcomes: A Population-Based Study. Diabetes Care. PMID 29351960 DOI: 10.2337/Dc17-2012 |
0.365 |
|
| 2018 |
Goldvaser H, Barnes TA, Šeruga B, Cescon DW, Ocaña A, Ribnikar D, Amir E. Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute. 110. PMID 28922781 DOI: 10.1093/Jnci/Djx141 |
0.456 |
|
| 2018 |
Goldvaser H, Ribnikar D, Majeed H, Ocana A, Amir E. Absolute benefit from adjuvant chemotherapy in triple negative breast cancer (TNBC): A systemic review and meta-analysis. Journal of Clinical Oncology. 36: e12501-e12501. DOI: 10.1200/Jco.2018.36.15_Suppl.E12501 |
0.421 |
|
| 2018 |
Ribnikar D, Goldvaser H, Ocana A, Templeton AJ, Seruga B, Amir E. Safety and tolerability of cancer drugs studied in phase 3 randomized controlled trials (RCTs) over the last decade. Journal of Clinical Oncology. 36: 6588-6588. DOI: 10.1200/Jco.2018.36.15_Suppl.6588 |
0.377 |
|
| 2018 |
Veitch ZWN, Cescon DW, Elston S, Lien S, Yang C, Wang BX, Berman HK, Butler MO, Amir E, Elser C, Hakgor S, Giesler A, Pugh TJ, Ohashi PS, Siu LL, et al. Phase II (INSPIRE) trial of pembrolizumab (pembro) with serial immune and genomic profiling in patients (pts) with metastatic triple negative breast cancer (mTNBC). Journal of Clinical Oncology. 36: 1094-1094. DOI: 10.1200/Jco.2018.36.15_Suppl.1094 |
0.312 |
|
| 2018 |
Chia SKL, Bedard PL, Hilton J, Amir E, Gelmon KA, Goodwin RA, Villa D, Cabanero M, Ritter H, Tu D, Tsao MS, Seymour L. A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies (CCTG IND.229)[NCT02649686]. Journal of Clinical Oncology. 36: 1029-1029. DOI: 10.1200/Jco.2018.36.15_Suppl.1029 |
0.339 |
|
| 2018 |
Goldvaser H, Ribnikar D, Fazelzad R, Seruga B, Templeton A, Ocana A, Amir E. Abstract P3-17-02: Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P3-17-02 |
0.393 |
|
| 2018 |
Goldvaser H, Algorashi I, Ribnikar D, Majeed H, Ocana A, Seruga B, Templeton A, Amir E. Abstract P3-12-04: Efficacy of extended adjuvant aromatase inhibitors in subgroups of women with early breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P3-12-04 |
0.396 |
|
| 2018 |
Molto Valiente C, Borrell M, Ocana Fernandez A, Templeton A, del Carpio L, Del Paggio J, Barnadas A, Booth C, Tibau A, Amir E. Magnitude of clinical benefit of cancer drugs approved based on single-arm trials (SAT) by the US Food and Drug Administration (FDA) Annals of Oncology. 29: viii564. DOI: 10.1093/Annonc/Mdy297.006 |
0.36 |
|
| 2018 |
Goldvaser H, Fyles A, Shepshelovich D, Amir E, Korzets Y. Toxicity and clinical outcomes of partial breast irradiation (PBI) compared to whole breast irradiation (WBI) for early stage breast cancer: A systematic review and meta-analysis. Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy270.241 |
0.401 |
|
| 2018 |
Meloche J, Nolan M, Amir E, Brezden-Masley C, Yan A, Thampinathan B, Woo A, Bernd W, Thavendiranathan P. TEMPORAL CHANGES IN LEFT ATRIAL FUNCTION IN WOMEN WITH HER2+ BREAST CANCER RECEIVING SEQUENTIAL ANTHRACYCLINES AND TRASTUZUMAB THERAPY Journal of the American College of Cardiology. 71: A1524. DOI: 10.1016/S0735-1097(18)32065-5 |
0.397 |
|
| 2018 |
Selam MA, Amir E, Brezden-Masley C, Connelly K, Michalowska M, Wintersperger BJ, Thavendiranathan P. VENTRICULAR REMODELING IN EARLY STAGE BREAST CANCER PATIENTS RECEIVING SEQUENTIAL ANTHRACYCLINE AND TRASTUZUMAB THERAPY: A CARDIAC MRI STUDY Journal of the American College of Cardiology. 71: A728. DOI: 10.1016/S0735-1097(18)31269-5 |
0.411 |
|
| 2018 |
Nolan MT, Meloche J, Amir E, Brezden CM, Thampinathan B, Michalowska M, Woo A, Wintersperger B, Thavendiranathan P. TEMPORAL CHANGES IN DIASTOLIC FUNCTION IN WOMEN WITH BREAST CANCER RECEIVING SEQUENTIAL THERAPY WITH ANTHRACYCLINE AND TRASTUZUMAB Journal of the American College of Cardiology. 71: A689. DOI: 10.1016/S0735-1097(18)31230-0 |
0.39 |
|
| 2018 |
Nolan MT, Aghel N, Amir E, Liu S, Silversides C, Maxwell C, Thavendiranathan P. PREGNANCY OUTCOMES IN PATIENTS WITH AND WITHOUT CANCER-TREATMENT-RELATED CARDIAC DYSFUNCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS Journal of the American College of Cardiology. 71: A688. DOI: 10.1016/S0735-1097(18)31229-4 |
0.333 |
|
| 2018 |
Altaha M, Nolan M, Amir E, Connelly K, Brezden-Masley C, Yared K, Wintersperger B, Thavendiranathan P. LEFT AND RIGHT VENTRICULAR REMODELING IN PATIENTS WITH EARLY STAGE BREAST CANCER RECEIVING SEQUENTIAL ANTHRACYCLINE AND TRASTUZUMAB THERAPY - A CARDIAC MRI STUDY Canadian Journal of Cardiology. 34: S179-S180. DOI: 10.1016/J.Cjca.2018.07.133 |
0.369 |
|
| 2017 |
Zer A, Prince RM, Amir E, Abdul Razak AR. Multi-agent chemotherapy in advanced soft tissue sarcoma (STS) - A systematic review and meta-analysis. Cancer Treatment Reviews. 63: 71-78. PMID 29253836 DOI: 10.1016/J.Ctrv.2017.12.003 |
0.316 |
|
| 2017 |
Tibau A, Molto C, Ocana A, Templeton AJ, Del Carpio LP, Del Paggio JC, Barnadas A, Booth CM, Amir E. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. Journal of the National Cancer Institute. PMID 29244173 DOI: 10.1093/Jnci/Djx232 |
0.311 |
|
| 2017 |
Perez-Peña J, Corrales-Sánchez V, Amir E, Pandiella A, Ocana A. Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers. Scientific Reports. 7: 17530. PMID 29235520 DOI: 10.1038/S41598-017-17836-7 |
0.401 |
|
| 2017 |
Porta-Sánchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, Thavendiranathan P. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. Journal of the American Heart Association. 6. PMID 29217664 DOI: 10.1161/Jaha.117.007724 |
0.402 |
|
| 2017 |
Pezo RC, Chen TW, Berman HK, Mulligan AM, Razak AA, Siu LL, Cescon DW, Amir E, Elser C, Warr DG, Sridhar SS, Yu C, Wang L, Stockley TL, Kamel-Reid S, et al. Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer. Breast Cancer Research and Treatment. PMID 29177603 DOI: 10.1007/S10549-017-4580-2 |
0.397 |
|
| 2017 |
Ribnikar D, Goldvaser H, Ocana A, Templeton AJ, Seruga B, Amir E. Reporting of Randomized Trials in Common Cancers in the Lay Media. Oncology. PMID 29151109 DOI: 10.1159/000484630 |
0.389 |
|
| 2017 |
Gonzalez-Conchas GA, Rodriguez-Romo L, Hernandez-Barajas D, Gonzalez-Guerrero JF, Rodriguez-Fernandez IA, Verdines-Perez A, Templeton AJ, Ocana A, Seruga B, Tannock IF, Amir E, Vera-Badillo FE. Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis. Cancer Treatment Reviews. 62: 1-8. PMID 29126017 DOI: 10.1016/J.Ctrv.2017.10.008 |
0.51 |
|
| 2017 |
Srikanthan A, Mai H, Penner N, Amir E, Laupacis A, Sabharwal M, Chan KKW. Impact of the pan-Canadian Oncology Drug Review on provincial concordance with respect to cancer drug funding decisions and time to funding. Current Oncology (Toronto, Ont.). 24: 295-301. PMID 29089796 DOI: 10.3747/Co.24.3648 |
0.313 |
|
| 2017 |
Goldvaser H, AlGorashi I, Ribnikar D, Seruga B, Templeton AJ, Ocana A, Amir E. Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis. Cancer Treatment Reviews. 60: 53-59. PMID 28881223 DOI: 10.1016/J.Ctrv.2017.08.008 |
0.46 |
|
| 2017 |
Puts MTE, Sattar S, Kulik M, MacDonald ME, McWatters K, Lee K, Brennenstuhl S, Jang R, Amir E, Krzyzanowska MK, Joshua AM, Monette J, Wan-Chow-Wah D, Alibhai SMH. A randomized phase II trial of geriatric assessment and management for older cancer patients. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. PMID 28741175 DOI: 10.1007/S00520-017-3820-7 |
0.327 |
|
| 2017 |
Goldvaser H, Ribnikar D, Fazelzad R, Seruga B, Templeton AJ, Ocana A, Amir E. Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer. Cancer Treatment Reviews. 59: 46-53. PMID 28734183 DOI: 10.1016/J.Ctrv.2017.06.007 |
0.39 |
|
| 2017 |
Barnes TA, Amir E. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. British Journal of Cancer. PMID 28704840 DOI: 10.1038/Bjc.2017.220 |
0.32 |
|
| 2017 |
Ethier JL, Desautels DN, Amir E, MacKay H. Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. Gynecologic Oncology. PMID 28689667 DOI: 10.1016/J.Ygyno.2017.07.002 |
0.348 |
|
| 2017 |
Natori A, Ethier JL, Amir E, Cescon DW. Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials. European Journal of Cancer (Oxford, England : 1990). 77: 40-47. PMID 28355581 DOI: 10.1016/j.ejca.2017.02.024 |
0.341 |
|
| 2017 |
Ethier JL, Prince RM, Amir E. Bone Modifier Use as Adjuvant Therapy for Early Breast Cancer. Current Oncology Reports. 19: 15. PMID 28251493 DOI: 10.1007/s11912-017-0577-6 |
0.317 |
|
| 2017 |
Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Research : Bcr. 19: 2. PMID 28057046 DOI: 10.1186/S13058-016-0794-1 |
0.426 |
|
| 2017 |
Alcaraz-Sanabria AL, Nieto-Jimenez C, Corrales-Sanchez V, Serrano-Oviedo L, Serrano-Heras G, Pretel FA, Montero JC, Burgos M, Llopis J, Galan-Moya EM, Amir E, Pandiella A, Ocana A. Synthetic lethality interaction between aurora kinases and CHEK1 inhibitors in ovarian cancer. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E17089 |
0.303 |
|
| 2017 |
Goldvaser H, Ribnikar D, Barnes TA, Cescon DW, Ocana A, Amir E. Toxicity of extended adjuvant aromatase inhibitors therapy in postmenopausal breast cancer patients: A systematic review and meta-analysis. Journal of Clinical Oncology. 35: 549-549. DOI: 10.1200/Jco.2017.35.15_Suppl.549 |
0.467 |
|
| 2017 |
Flaum N, Hubner R, Valle JW, Amir E, McNamara MG. Adjuvant chemotherapy and outcome in patients (pts) with nodal (N-) and resection margin negative (R0) pancreatic adenocarcinoma (PC): A systematic review and meta-analysis. Journal of Clinical Oncology. 35: 4114-4114. DOI: 10.1200/Jco.2017.35.15_Suppl.4114 |
0.32 |
|
| 2017 |
Natori A, Ethier J, Amir E, Cescon D. Abstract P5-14-05: Capecitabine in early breast cancer: A meta-analysis of randomized controlled trials Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P5-14-05 |
0.427 |
|
| 2017 |
Stjepanovic N, Kim R, Wilson M, Mandilaras V, Berman H, Amir E, Cescon D, Elser C, Armel SR, McCuaig J, Volenik A, Demsky R, Chow H, Misyura M, Wang L, et al. Abstract P3-09-05: Clinical outcome of patients with advanced triple negative breast cancer with germline and somatic variants in homologous recombination gene Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-09-05 |
0.371 |
|
| 2017 |
Stjepanovic N, Garg S, Berman H, Warr D, Amir E, Cescon D, Elser C, Wang L, Kamel-Reid S, Siu L, Bedard P, Stockley T. Abstract P2-05-19: Impact of TP53 functional mutation type on clinical outcomes of advanced breast cancer patients Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P2-05-19 |
0.391 |
|
| 2017 |
Paoletti C, Regan M, Liu M, Marcom P, Hart L, Smith J, Tedesco K, Amir E, Krop I, DeMichele A, Goodwin P, Block M, Aung K, Cannell E, Darga E, et al. Abstract P1-01-01: Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P1-01-01 |
0.434 |
|
| 2017 |
Abdel-Qadir H, Thavendiranathan P, Austin P, Lee D, Amir E, Tu J, Ma H, Fung K, Anderson G. 2020The spectrum of cardiovascular disease after early stage breast cancer: a population-based cohort study European Heart Journal. 38. DOI: 10.1093/Eurheartj/Ehx502.2020 |
0.367 |
|
| 2017 |
Puy MB, Valiente CM, Fernandez AO, Templeton A, Seruga B, Gich I, Barnadas A, Amir E, Tibau A. Clinical benefit of randomized controlled trials (RCT) supporting US Food and Drug Administration (FDA) conversion from accelerated to full approval Annals of Oncology. 28: v642. DOI: 10.1093/Annonc/Mdx440.065 |
0.315 |
|
| 2017 |
Valiente CM, Tibau A, Fernandez AO, Templeton A, del Carpio Huerta L, Del Paggio J, Barnadas A, Booth C, Amir E. Comparison of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in clinical trials supporting US Food and Drug Administration (FDA) approval of orphan vs. non-orphan drugs Annals of Oncology. 28: v642. DOI: 10.1093/Annonc/Mdx440.063 |
0.31 |
|
| 2017 |
Ribnikar D, Goldvaser H, Ocana Fernandez A, Templeton A, Seruga B, Amir E. Reporting of results of randomized trials in common cancers in the lay media Annals of Oncology. 28: v513. DOI: 10.1093/Annonc/Mdx385.005A |
0.389 |
|
| 2017 |
Molto Valiente C, Amir E, Ocana Fernandez A, Templeton A, del Carpio Huerta L, Del Paggio J, Barnadas A, Booth C, Tibau A. Magnitude of clinical benefit of randomized controlled trials supporting US Food and Drug Administration approval of drugs for solid tumours Annals of Oncology. 28: v511. DOI: 10.1093/Annonc/Mdx385.001 |
0.312 |
|
| 2017 |
Abdel-Qadir H, Austin P, Thavendiranathan P, Fang J, Fung K, Amir E, Lee D, Tu J, Anderson G. A RISK SCORE FOR PREDICTING CARDIOVASCULAR EVENTS AFTER EARLY STAGE BREAST CANCER Canadian Journal of Cardiology. 33: S25-S26. DOI: 10.1016/J.Cjca.2017.07.071 |
0.367 |
|
| 2016 |
Prince RM, Amir E. Update in treatment of early breast cancer in post-menopausal women. Expert Review of Endocrinology & Metabolism. 11: 243-252. PMID 30058935 DOI: 10.1080/17446651.2016.1175937 |
0.403 |
|
| 2016 |
Thavendiranathan P, Amir E. Left Ventricular Dysfunction With Trastuzumab Therapy: Is Primary Prevention the Best Option? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016710038. PMID 28029315 DOI: 10.1200/Jco.2016.71.0038 |
0.395 |
|
| 2016 |
Tannock IF, Amir E, Booth CM, Niraula S, Ocana A, Seruga B, Templeton AJ, Vera-Badillo F. Relevance of randomised controlled trials in oncology. The Lancet. Oncology. 17: e560-e567. PMID 27924754 DOI: 10.1016/S1470-2045(16)30572-1 |
0.521 |
|
| 2016 |
Abdel-Qadir H, Austin PC, Lee DS, Amir E, Tu JV, Thavendiranathan P, Fung K, Anderson GM. A Population-Based Study of Cardiovascular Mortality Following Early-Stage Breast Cancer. Jama Cardiology. PMID 27732702 DOI: 10.1001/Jamacardio.2016.3841 |
0.385 |
|
| 2016 |
Abdel-Qadir H, Amir E, Fischer HD, Fu L, Austin PC, Harvey PJ, Rochon PA, Lee DS, Anderson GM. The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer. European Journal of Cancer (Oxford, England : 1990). 68: 11-21. PMID 27693889 DOI: 10.1016/J.Ejca.2016.08.022 |
0.395 |
|
| 2016 |
Vera-Badillo FE, Napoleone M, Krzyzanowska MK, Alibhai SM, Chan AW, Ocana A, Templeton AJ, Seruga B, Amir E, Tannock IF. Honorary and ghost authorship in reports of randomised clinical trials in oncology. European Journal of Cancer (Oxford, England : 1990). 66: 1-8. PMID 27500368 DOI: 10.1016/J.Ejca.2016.06.023 |
0.477 |
|
| 2016 |
Seruga B, Templeton AJ, Badillo FE, Ocana A, Amir E, Tannock IF. Under-reporting of harm in clinical trials. The Lancet. Oncology. 17: e209-19. PMID 27301048 DOI: 10.1016/S1470-2045(16)00152-2 |
0.514 |
|
| 2016 |
Gómez García S, Clemons M, Amir E. Rethinking end-points for bone-targeted therapy in advanced cancer. European Journal of Cancer (Oxford, England : 1990). 63: 105-109. PMID 27299662 DOI: 10.1016/J.Ejca.2016.05.014 |
0.352 |
|
| 2016 |
Ethier JL, Amir E. The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment. Molecular Diagnosis & Therapy. PMID 27235162 DOI: 10.1007/S40291-016-0209-0 |
0.412 |
|
| 2016 |
Srikanthan A, Amir E, Warner E. Does a dedicated program for young breast cancer patients affect the likelihood of fertility preservation discussion and referral? Breast (Edinburgh, Scotland). 27: 22-6. PMID 27212696 DOI: 10.1016/J.Breast.2016.02.012 |
0.366 |
|
| 2016 |
Ocana A, Amir E, Tannock IF. Toward Value-Based Pricing to Boost Cancer Research and Innovation. Cancer Research. 76: 3127-9. PMID 27197164 DOI: 10.1158/0008-5472.Can-15-3179 |
0.475 |
|
| 2016 |
Nathan PC, Amir E, Abdel-Qadir H. Cardiac Outcomes in Survivors of Pediatric and Adult Cancers. The Canadian Journal of Cardiology. PMID 27179545 DOI: 10.1016/J.Cjca.2016.02.065 |
0.349 |
|
| 2016 |
Vera-Badillo FE, Napoleone M, Krzyzanowska MK, Alibhai SM, Chan AW, Ocana A, Seruga B, Templeton AJ, Amir E, Tannock IF. Bias in reporting of randomised clinical trials in oncology. European Journal of Cancer (Oxford, England : 1990). 61: 29-35. PMID 27151552 DOI: 10.1016/J.Ejca.2016.03.066 |
0.525 |
|
| 2016 |
Templeton AJ, Gonzalez LD, Vera-Badillo FE, Tibau A, Goldstein R, Šeruga B, Srikanthan A, Pandiella A, Amir E, Ocana A. Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression. Plos One. 11: e0154789. PMID 27149669 DOI: 10.1371/Journal.Pone.0154789 |
0.325 |
|
| 2016 |
Abdel-Qadir H, Amir E, Thavendiranathan P. Prevention, Detection, and Management of Chemotherapy-Related Cardiac Dysfunction. The Canadian Journal of Cardiology. PMID 27118058 DOI: 10.1016/J.Cjca.2016.01.028 |
0.357 |
|
| 2016 |
Ocaña A, Pérez-Peña J, Alcaraz-Sanabria A, Sánchez-Corrales V, Nieto-Jiménez C, Templeton AJ, Seruga B, Pandiella A, Amir E. In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases. Oncotarget. PMID 26992217 DOI: 10.18632/Oncotarget.8118 |
0.373 |
|
| 2016 |
Zer A, Prince RM, Amir E, Abdul Razak A. Evolution of Randomized Trials in Advanced/Metastatic Soft Tissue Sarcoma: Endpoint Selection, Surrogacy, and Quality of Reporting. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26951308 DOI: 10.1200/Jco.2015.64.3437 |
0.322 |
|
| 2016 |
Graham J, Pitz M, Gordon V, Grenier D, Amir E, Niraula S. Clinical predictors of benefit from fulvestrant in advanced breast cancer: A Meta-analysis of randomized controlled trials. Cancer Treatment Reviews. 45: 1-6. PMID 26922660 DOI: 10.1016/J.Ctrv.2016.02.004 |
0.445 |
|
| 2016 |
Ocaña A, Pérez-Peña J, Díez-González L, Sánchez-Corrales V, Templeton A, Seruga B, Amir E, Pandiella A. Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer. Breast Cancer Research and Treatment. 156: 1-8. PMID 26897635 DOI: 10.1007/S10549-016-3720-4 |
0.325 |
|
| 2016 |
Srikanthan A, Vera-Badillo F, Ethier J, Goldstein R, Templeton AJ, Ocana A, Seruga B, Amir E. Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies Cancer Treatment Reviews. 43: 67-73. PMID 26827694 DOI: 10.1016/J.Ctrv.2015.12.006 |
0.372 |
|
| 2016 |
AlHashem HY, Al-Mubarak M, Vera-Badillo FE, Templeton AJ, Ocana A, Seruga B, Amir E. Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials. Clinical Oncology (Royal College of Radiologists (Great Britain)). 28: 283-91. PMID 26542275 DOI: 10.1016/J.Clon.2015.09.010 |
0.322 |
|
| 2016 |
Tran B, Ruiz Morales JM, González-Billalabeitia E, Amir E, Seidel CA, Bokemeyer C, Fankhauser CD, Hermanns T, Rumyantsev A, Tryakin A, Goncalves MB, Fléchon A, Cheng T, Castellano DE, Garcia del Muro X, et al. Large retroperitoneal lymphadenopathy (RPLN) and increased risk of venous thromboembolism (VTE) in patients (pts) with metastatic germ cell tumours (mGCT): A Global Germ Cell Cancer Group (G3) Study. Journal of Clinical Oncology. 34: e16058-e16058. DOI: 10.1200/Jco.2016.34.15_Suppl.E16058 |
0.312 |
|
| 2016 |
Ethier J, Ocana A, Casas M, Sanchez-Arago M, Caballero R, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz M, Santaballa A, Rodriguez CA, Crespo C, Ramos Vazquez M, Gracia JM, ... ... Amir E, et al. Outcomes of single versus double hormone receptor positive breast cancer. Journal of Clinical Oncology. 34: 569-569. DOI: 10.1200/Jco.2016.34.15_Suppl.569 |
0.405 |
|
| 2016 |
Prince RM, DÃez L, Alcaraz-Sanabria A, Ethier J, Ocana A, Seruga B, Templeton AJ, Amir E. Treatment-related side effects as predictors of efficacy of check-point inhibitors (CPIs). Journal of Clinical Oncology. 34: 3062-3062. DOI: 10.1200/Jco.2016.34.15_Suppl.3062 |
0.315 |
|
| 2016 |
Srikanthan A, Amir E, Warner E. Abstract P6-12-02: Association between a dedicated program for young breast cancer patients and discussion about fertility preservation Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P6-12-02 |
0.417 |
|
| 2016 |
Niraula S, Pitz M, Gordon V, Grenier D, Amir E, Brandes L. Abstract P5-14-02: Clinical predictors of benefit from fulvestrant in advanced breast cancer: A meta-analysis of randomized controlled trials Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P5-14-02 |
0.491 |
|
| 2016 |
Srikanthan A, Bedard P, Goldstein S, Templeton A, Amir E. Abstract P2-08-05: Association between the neutrophil-to-lymphocyte ratio (NLR) and the 21-gene recurrence score Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P2-08-05 |
0.358 |
|
| 2016 |
Lohmann A, Chang M, Dowling R, Ennis M, Amir E, Elser C, Brezden-Masley C, Vandenberg T, Lee E, Fazae K, Stambolic V, Goodwin P. Abstract P2-02-12: Association of inflammatory and tumor markers with circulating tumor cells in metastatic breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P2-02-12 |
0.387 |
|
| 2016 |
Dowling R, Chang M, Lohmann A, Ennis M, Amir E, Elser C, Brezden-Masley C, Vandenberg T, Lee E, Fazaee K, Stambolic V, Goodwin P. Abstract P2-02-09: Obesity associated factors are inversely associated with circulating tumor cells in metastatic breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P2-02-09 |
0.343 |
|
| 2016 |
Fernandez AO, Templeton A, Casas M, Sánchez-Aragó M, Caballero R, Lescure AR, Ruiz A, Alba E, Calvo L, Ruiz M, Santaballa A, Rodríguez C, Crespo C, Ramos M, Marco JG, ... ... Amir E, et al. Prognostic role for derived neutrophil-to-lymphocyte ratio in early breast cancer Annals of Oncology. 27: vi43. DOI: 10.1093/Annonc/Mdw364.02 |
0.404 |
|
| 2015 |
Zist A, Amir E, Ocana AF, Seruga B. Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel. Radiology and Oncology. 49: 402-8. PMID 26834528 DOI: 10.1515/Raon-2015-0038 |
0.31 |
|
| 2015 |
Jacobs C, Amir E, Paterson A, Zhu X, Clemons M. Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting. Journal of Bone Oncology. 4: 54-58. PMID 26579489 DOI: 10.1016/J.Jbo.2015.06.001 |
0.422 |
|
| 2015 |
Seruga B, Ocana A, Amir E, Tannock IF. Failures in Phase III: Causes and Consequences. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 4552-60. PMID 26473191 DOI: 10.1158/1078-0432.Ccr-15-0124 |
0.518 |
|
| 2015 |
Ocana A, Ethier JL, Díez-González L, Corrales-Sánchez V, Srikanthan A, Gascón-Escribano MJ, Templeton AJ, Vera-Badillo F, Seruga B, Niraula S, Pandiella A, Amir E. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget. 6: 39538-49. PMID 26446908 DOI: 10.18632/Oncotarget.5946 |
0.373 |
|
| 2015 |
Dupuy F, Tabariès S, Andrzejewski S, Dong Z, Blagih J, Annis MG, Omeroglu A, Gao D, Leung S, Amir E, Clemons M, Aguilar-Mahecha A, Basik M, Vincent EE, St-Pierre J, et al. PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer. Cell Metabolism. 22: 577-89. PMID 26365179 DOI: 10.1016/J.Cmet.2015.08.007 |
0.348 |
|
| 2015 |
Calleja A, Poulin F, Khorolsky C, Shariat M, Bedard PL, Amir E, Rakowski H, McDonald M, Delgado D, Thavendiranathan P. Right Ventricular Dysfunction in Patients Experiencing Cardiotoxicity during Breast Cancer Therapy. Journal of Oncology. 2015: 609194. PMID 26339242 DOI: 10.1155/2015/609194 |
0.376 |
|
| 2015 |
Ocana A, Vera-Badillo F, Templeton A, Tannock I, Amir E. Response. Journal of the National Cancer Institute. 107. PMID 26283612 DOI: 10.1093/jnci/djv244 |
0.302 |
|
| 2015 |
Dranitsaris G, Cohen RB, Acton G, Keltner L, Price M, Amir E, Podack ER, Schreiber TH. Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer Agents. Journal of Immunotherapy (Hagerstown, Md. : 1997). 38: 259-66. PMID 26261889 DOI: 10.1097/Cji.0000000000000089 |
0.402 |
|
| 2015 |
Abdel-Qadir H, Amir E, Thavendiranathan P. The use of myocardial strain and newer echocardiography imaging techniques in cancer patients. Future Oncology (London, England). 11: 2035-41. PMID 26198833 DOI: 10.2217/Fon.15.122 |
0.369 |
|
| 2015 |
Chan M, Chang MC, González R, Lategan B, del Barco E, Vera-Badillo F, Quesada P, Goldstein R, Cruz I, Ocana A, Cruz JJ, Amir E. Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer. Plos One. 10: e0132449. PMID 26161666 DOI: 10.1371/Journal.Pone.0132449 |
0.354 |
|
| 2015 |
Niraula S, Ocana A, Amir E. One step forward, two steps back: The story of everolimus in advanced breast cancer. Breast (Edinburgh, Scotland). 24: 529-31. PMID 26112664 DOI: 10.1016/J.Breast.2015.04.006 |
0.422 |
|
| 2015 |
Vera-Badillo FE, Chang MC, Kuruzar G, Ocana A, Templeton AJ, Seruga B, Goldstein R, Bedard PL, Tannock IF, Amir E. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer. Journal of Clinical Pathology. PMID 26076967 DOI: 10.1136/Jclinpath-2015-203012 |
0.526 |
|
| 2015 |
Jacobs C, Hutton B, Mazzarello S, Smith S, Joy A, Amir E, Ibrahim MF, Gregario N, Daigle K, Eggert L, Clemons M. Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy-a survey of health care providers and patients. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. PMID 25933700 DOI: 10.1007/S00520-015-2731-8 |
0.382 |
|
| 2015 |
Srikanthan A, Ethier JL, Ocana A, Seruga B, Krzyzanowska MK, Amir E. Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study. Plos One. 10: e0122735. PMID 25815472 DOI: 10.1371/Journal.Pone.0122735 |
0.334 |
|
| 2015 |
Ocaña A, Diez-Gónzález L, Adrover E, Fernández-Aramburo A, Pandiella A, Amir E. Tumor-infiltrating lymphocytes in breast cancer: ready for prime time? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1298-9. PMID 25753437 DOI: 10.1200/Jco.2014.59.7286 |
0.389 |
|
| 2015 |
Templeton AJ, Ace O, Amir E, Vera-Badillo F, Ocana A, Pond GR, Tannock IF. Influence of censoring on conclusions of trials for women with metastatic breast cancer. European Journal of Cancer (Oxford, England : 1990). 51: 721-4. PMID 25728257 DOI: 10.1016/J.Ejca.2014.12.016 |
0.582 |
|
| 2015 |
Ocana A, Seruga B, Amir E. Pathological complete response in breast cancer. Lancet (London, England). 385: 113. PMID 25706463 DOI: 10.1016/S0140-6736(15)60015-0 |
0.43 |
|
| 2015 |
Srikanthan A, Tran B, Beausoleil M, Jewett MA, Hamilton RJ, Sturgeon JF, O'Malley M, Anson-Cartwright L, Chung PW, Warde PR, Winquist E, Moore MJ, Amir E, Bedard PL. Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 582-7. PMID 25605848 DOI: 10.1200/Jco.2014.58.6537 |
0.315 |
|
| 2015 |
van Soest RJ, Templeton AJ, Vera-Badillo FE, Mercier F, Sonpavde G, Amir E, Tombal B, Rosenthal M, Eisenberger MA, Tannock IF, de Wit R. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 743-9. PMID 25515657 DOI: 10.1093/Annonc/Mdu569 |
0.521 |
|
| 2015 |
Vera-Badillo FE, Templeton AJ, Duran I, Ocana A, de Gouveia P, Aneja P, Knox JJ, Tannock IF, Escudier B, Amir E. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. European Urology. 67: 740-9. PMID 24882670 DOI: 10.1016/J.Eururo.2014.05.010 |
0.463 |
|
| 2015 |
Blanchette PS, Lo A, Ng P, Razak A, Amir E, Hogg D, Blackstein ME, Gupta AA. Irinotecan and temozolomide in adults with recurrent sarcoma Journal of Solid Tumors. 5. DOI: 10.5430/Jst.V5N2P105 |
0.307 |
|
| 2015 |
Alimohamed NS, Templeton AJ, Knox JJ, Lin X, Simantov R, Xie W, Lawrence NJ, Broom RJ, Fay AP, Rini BI, Bjarnason GA, Smoragiewicz M, Kollmannsberger CK, Kanesvaran R, Wells C, ... Amir E, et al. Change in neutrophil to lymphocyte ratio as a prognostic and predictive marker in response to targeted therapy for metastatic renal cell carcinoma. Journal of Clinical Oncology. 33: 404-404. DOI: 10.1200/Jco.2015.33.7_Suppl.404 |
0.338 |
|
| 2015 |
Puts M, Sattar S, McWatters K, Lee K, Amir E, Krzyzanowska MK, Joshua AM, Monette J, Wan-Chow-Wah D, Jang RW, Alibhai SM. A feasibility trial of geriatric assessment and integrated care plan for older cancer patients. Journal of Clinical Oncology. 33: TPS9634-TPS9634. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps9634 |
0.373 |
|
| 2015 |
Clarke KV, Amir E, Berman HK, Maganti M, Sridhar SS. Association between pretreatment neutrophil to lymphocyte ratio (NLR) and complete pathological response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NACT). Journal of Clinical Oncology. 33: e11588-e11588. DOI: 10.1200/Jco.2015.33.15_Suppl.E11588 |
0.438 |
|
| 2015 |
Srikanthan A, Amir E, Gupta AA, Baxter NN, Kennedy ED. The price of survival: Breast cancer patient preferences about fertility. Journal of Clinical Oncology. 33: 9561-9561. DOI: 10.1200/Jco.2015.33.15_Suppl.9561 |
0.409 |
|
| 2015 |
Stjepanovic N, Wilson MK, Oza AM, Clarke B, Berman HK, Amir E, Mackay H, Shaw P, Butler MO, Mulligan AM, Milea A, Ahmed L, Volenik A, Wang L, Pugh TJ, et al. Somatic mutation profiling of advanced breast and ovarian cancers according to germline BRCA1/2 mutation status. Journal of Clinical Oncology. 33: 1532-1532. DOI: 10.1200/Jco.2015.33.15_Suppl.1532 |
0.365 |
|
| 2015 |
Zer A, Prince RM, Amir E, Razak ARA. Forty years of randomized trials in advanced/metastatic soft tissue sarcoma (STS): Endpoint selection, surrogacy and quality of reporting. Journal of Clinical Oncology. 33: 10513-10513. DOI: 10.1200/Jco.2015.33.15_Suppl.10513 |
0.345 |
|
| 2015 |
McNamara M, Backen A, Lamarca A, Hubner R, Valle J, Amir E. 2293 Targeting the epidermal growth factor receptor (EGFR) in addition to chemotherapy in patients (pts) with advanced pancreas cancer: A systematic review and meta-analysis European Journal of Cancer. 51: S430. DOI: 10.1016/S0959-8049(16)31209-6 |
0.347 |
|
| 2015 |
Vera Badillo F, Gonzalez-Guerrero J, Gonzalez-Conchas G, Rodriguez-Fernandez I, Verdines-Perez A, Templeton A, Ocana A, Seruga B, Tannock I, Amir E. 1973 Epidermal growth factor receptor (EGFR) over-expression and outcomes in early breast cancer: A systematic review and meta-analysis European Journal of Cancer. 51: S324-S325. DOI: 10.1016/S0959-8049(16)30921-2 |
0.526 |
|
| 2015 |
Guerra R, Toloi D, Tibau A, Ocana A, Seruga B, Vera-Badillo F, Amir E, Tannock I, Templeton A. 1229 Industry-Sponsored Posters at Major Oncology Conferences: Science or Marketing? European Journal of Cancer. 51: S183. DOI: 10.1016/S0959-8049(16)30533-0 |
0.4 |
|
| 2015 |
Anguera G, Tibau A, Andrés-Pretel F, Andrés M, Seruga B, Templeton A, Jerez Y, Vera-Badillo F, Barnadas A, Martin M, Amir E, Ocańa A. 1215 Role of cooperative groups and funding source in clinical studies that support approved therapy for breast cancer European Journal of Cancer. 51: S176-S177. DOI: 10.1016/S0959-8049(16)30519-6 |
0.413 |
|
| 2015 |
Ethier J, Dýez-González L, Corrales-Sánchez V, Srikanthan A, Gascón-Escribano M, Templeton A, Vera-Badillo F, Seruga B, Niraula S, Pandiella A, Amir E, Ocana A. 1204 Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs European Journal of Cancer. 51: S172-S173. DOI: 10.1016/S0959-8049(16)30508-1 |
0.338 |
|
| 2015 |
Calleja A, Poulin F, Khorolsky K, Bedard PL, Shariat M, Amir E, Rakowski H, McDonald M, Delgado D, Thavendiranathan P. RIGHT VENTRICULAR DYSFUNCTION IN PATIENTS WITH BREAST CANCER EXPERIENCING CARDIOTOXICITY DURING TRASTUZUMAB THERAPY Journal of the American College of Cardiology. 65: A940. DOI: 10.1016/S0735-1097(15)60940-8 |
0.357 |
|
| 2014 |
Hansen A, Geddie W, Boerner S, Ghai S, Berman H, Serra S, Roehrl M, Joshua AM, Oza AM, Moore M, Amir E, Usmani T, Giesler A, Amin N, Zhang T, et al. 1612PFINE NEEDLE BIOPSIES ARE FEASIBLE AS A MINIMALLY INVASIVE MEANS FOR TARGETED NEXT GENERATION SEQUENCING IN ADVANCED SOLID TUMORS. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv558. PMID 28172381 DOI: 10.1093/Annonc/Mdu358.43 |
0.318 |
|
| 2014 |
Templeton A, Knox J, Mitchell N, Broom R, Choueiri TK, McDermott DF, Fay A, Rini BI, Alvarez A, Bjarnason GA, Smoragiewicz M, Kollmannsberger CK, Kanesvaran R, North S, Alimohamed N, ... ... Amir E, et al. 817PPROGNOSTIC IMPACT OF CHANGE IN NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IN RESPONSE TO TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA (MRCC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv284. PMID 28172100 DOI: 10.1093/Annonc/Mdu337.10 |
0.308 |
|
| 2014 |
Zhu X, Amir E, Singh G, Clemons M, Addison C. Bone-targeted therapy for metastatic breast cancer-Where do we go from here? A commentary from the BONUS 8 meeting. Journal of Bone Oncology. 3: 1-4. PMID 26909291 DOI: 10.1016/J.Jbo.2014.01.001 |
0.36 |
|
| 2014 |
Addison CL, Pond GR, Zhao H, Mazzarello S, Vandermeer L, Goldstein R, Amir E, Clemons M. Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases. Springerplus. 3: 577. PMID 25332877 DOI: 10.1186/2193-1801-3-577 |
0.33 |
|
| 2014 |
Niraula S, Amir E, Vera-Badillo F, Seruga B, Ocana A, Tannock IF. Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3634-42. PMID 25267757 DOI: 10.1200/Jco.2014.55.8437 |
0.452 |
|
| 2014 |
Templeton AJ, Diez-Gonzalez L, Ace O, Vera-Badillo F, Seruga B, Jordán J, Amir E, Pandiella A, Ocaña A. Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis. Cancer Treatment Reviews. 40: 1048-55. PMID 25217796 DOI: 10.1016/J.Ctrv.2014.08.003 |
0.389 |
|
| 2014 |
Habbous S, Pang V, Xu W, Amir E, Liu G. Human papillomavirus and host genetic polymorphisms in carcinogenesis: a systematic review and meta-analysis. Journal of Clinical Virology : the Official Publication of the Pan American Society For Clinical Virology. 61: 220-9. PMID 25174543 DOI: 10.1016/J.Jcv.2014.07.019 |
0.312 |
|
| 2014 |
Vera-Badillo FE, Ocana A, Templeton AJ, Tibau A, Amir E, Tannock IF. Raising concern about the American Society of Clinical Oncology conflict of interest policy amendment. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3197. PMID 25092777 DOI: 10.1200/Jco.2014.56.2447 |
0.417 |
|
| 2014 |
Templeton AJ, Pezaro C, Omlin A, McNamara MG, Leibowitz-Amit R, Vera-Badillo FE, Attard G, de Bono JS, Tannock IF, Amir E. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer. 120: 3346-52. PMID 24995769 DOI: 10.1002/Cncr.28890 |
0.487 |
|
| 2014 |
Vera-Badillo FE, Napoleone M, Ocana A, Templeton AJ, Seruga B, Al-Mubarak M, AlHashem H, Tannock IF, Amir E. Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment. 146: 235-44. PMID 24928527 DOI: 10.1200/Jco.2014.32.15_Suppl.546 |
0.527 |
|
| 2014 |
Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Journal of the National Cancer Institute. 106: dju124. PMID 24875653 DOI: 10.1093/Jnci/Dju124 |
0.49 |
|
| 2014 |
Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, Seruga B, Ocaña A, Tannock IF, Amir E. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 1204-12. PMID 24793958 DOI: 10.1158/1055-9965.Epi-14-0146 |
0.483 |
|
| 2014 |
Erman A, Nugent A, Amir E, Coyte PC. Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer. Breast Cancer Research and Treatment. 145: 267-79. PMID 24771048 DOI: 10.1007/S10549-014-2950-6 |
0.34 |
|
| 2014 |
Addison CL, Bouganim N, Hilton J, Vandermeer L, Dent S, Amir E, Hopkins S, Kuchuk I, Segal R, Song X, Gertler S, Mazzarello S, Dranitsaris G, Ooi D, Pond G, et al. A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events Breast Cancer Research and Treatment. 144: 615-624. PMID 24638849 DOI: 10.1007/S10549-014-2906-X |
0.342 |
|
| 2014 |
McNamara MG, Templeton AJ, Maganti M, Walter T, Horgan AM, McKeever L, Min T, Amir E, Knox JJ. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. European Journal of Cancer (Oxford, England : 1990). 50: 1581-9. PMID 24630393 DOI: 10.1016/J.Ejca.2014.02.015 |
0.365 |
|
| 2014 |
Al-Mubarak M, Tibau A, Templeton AJ, Cescon DW, Ocana A, Seruga B, Amir E. Extended adjuvant tamoxifen for early breast cancer: a meta-analysis. Plos One. 9: e88238. PMID 24586311 DOI: 10.1200/Jco.2013.31.15_Suppl.539 |
0.422 |
|
| 2014 |
Seruga B, Zadnik V, Kuhar CG, Marinko T, Cufer T, Zakotnik B, Zorman D, Ocana A, Amir E. Association of aromatase inhibitors with coronary heart disease in women with early breast cancer. Cancer Investigation. 32: 99-104. PMID 24548302 DOI: 10.3109/07357907.2014.880452 |
0.369 |
|
| 2014 |
Horgan AM, Seruga B, Pond GR, Alibhai SM, Amir E, De Wit R, Eisenberger MA, Tannock IF. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. Journal of Geriatric Oncology. 5: 119-26. PMID 24495703 DOI: 10.1016/J.Jgo.2013.12.001 |
0.49 |
|
| 2014 |
Ocaña A, Freedman O, Amir E, Seruga B, Pandiella A. Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors. Cancer Metastasis Reviews. 33: 295-307. PMID 24338003 DOI: 10.1007/S10555-013-9451-7 |
0.33 |
|
| 2014 |
Vera-Badillo FE, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard PL, Al-Mubarak M, Seruga B, Tannock IF, Ocana A, Amir E. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. Journal of the National Cancer Institute. 106: djt319. PMID 24273215 DOI: 10.1093/Jnci/Djt319 |
0.551 |
|
| 2014 |
Templeton AJ, Omlin AG, Pezaro CJ, Kheoh TS, Leibowitz-Amit R, Vera-Badillo FE, Tannock I, Attard G, Amir E, De Bono JS. A prognostic score for patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post chemotherapy. Journal of Clinical Oncology. 32: 70-70. DOI: 10.1200/Jco.2014.32.4_Suppl.70 |
0.502 |
|
| 2014 |
Templeton AJ, Amir E, Aneja P, Vera-Badillo FE, Hermanns T, McNamara MG, Heng DYC, Knox JJ. Neutrophil to lymphocyte ratio and response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma. Journal of Clinical Oncology. 32: 477-477. DOI: 10.1200/Jco.2014.32.4_Suppl.477 |
0.313 |
|
| 2014 |
Vera-Badillo FE, Templeton A, Ocana A, deGouveia P, Aneja P, Knox JJ, Tannock I, Duran I, Escudier BJ, Amir E. Response to systemic therapy in non-clear cell renal cell carcinomas: A systematic review and meta-analysis. Journal of Clinical Oncology. 32: 425-425. DOI: 10.1200/Jco.2014.32.4_Suppl.425 |
0.501 |
|
| 2014 |
Niraula S, Amir E, Vera Badillo FE, Seruga B, Ocana A, Tannock I. Absolute risk and cost of management of toxicities of newly approved anticancer drugs: A meta-analysis. Journal of Clinical Oncology. 32: e17556-e17556. DOI: 10.1200/Jco.2014.32.15_Suppl.E17556 |
0.451 |
|
| 2014 |
Chan M, Chang M, Gonzalez R, Lategan B, del Barco E, Vera-Badillo FE, Quesada P, Goldstein R, Cruz I, Ocana A, Cruz JJ, Amir E. Clinical outcomes of estrogen receptor (ER)-negative and progesterone receptor (PgR)-positive invasive breast cancer. Journal of Clinical Oncology. 32: 567-567. DOI: 10.1200/Jco.2014.32.15_Suppl.567 |
0.389 |
|
| 2014 |
Vera-Badillo FE, Chang M, Kuruzar G, Ocana A, Templeton AJ, Seruga B, Al-Mubarak M, Goldstein R, Bedard PL, Tannock I, Amir E. Association between androgen receptor (AR) expression, Ki-67, and the 21-gene recurrence score in early breast cancer. Journal of Clinical Oncology. 32: 547-547. DOI: 10.1200/Jco.2014.32.15_Suppl.547 |
0.517 |
|
| 2014 |
Templeton AJ, Vera-Badillo FE, Mercier F, Sonpavde G, Amir E, Tombal BF, Rosenthal M, Tannock I. Prognostic role of derived neutrophil to lymphocyte ratio (dNLR) in men with metastatic castration resistant prostate cancer (mCRPC) treated in a phase 3 trial (VENICE). Journal of Clinical Oncology. 32: 5047-5047. DOI: 10.1200/Jco.2014.32.15_Suppl.5047 |
0.521 |
|
| 2014 |
Thavendiranathan P, Amir E, Bedard P, Crean A, Paul N, Nguyen ET, Wintersperger BJ. Regional myocardial edema detected by T2 mapping is a feature of cardiotoxicity in breast cancer patients receiving sequential therapy with anthracyclines and trastuzumab Journal of Cardiovascular Magnetic Resonance. 16. DOI: 10.1186/1532-429X-16-S1-P273 |
0.402 |
|
| 2014 |
Niraula S, Amir E, Seruga B, Vera-Badillo F, Ocana A, Tannock IF. 1386O_Prrisk Of Incremental Toxicities And Associated Costs Of New Anticancer Drugs: A Meta-Analysis Annals of Oncology. 25. DOI: 10.1093/Annonc/Mdu438.55 |
0.51 |
|
| 2014 |
Al Hashem H, Al-Mubarak M, Templeton A, Ocana A, Seruga B, Amir E. Impact of Geographic Region on Benefit of Anticancer Agents Evaluated in International Phase III Clinical Trials Annals of Oncology. 25: iv486. DOI: 10.1093/Annonc/Mdu353.2 |
0.331 |
|
| 2014 |
Tibau B, Bedard P, Vera-Badillo F, Templeton A, Ocana A, Seruga B, Barnadas A, Amir E. Author Financial Conflicts of Interest (Fcois) in Clinical Practice Guidelines (Cpgs) for Systemic Anti-Cancer Drugs Annals of Oncology. 25: iv486. DOI: 10.1093/Annonc/Mdu353.1 |
0.39 |
|
| 2014 |
Puts M, Krzyzanowska M, Amir E, Joshua A, Monette J, Wan-Chow-Wah D, Jang R, Alibhai S. A feasibility trial of geriatric assessment and management for older cancer patients Journal of Geriatric Oncology. 5: S47-S48. DOI: 10.1016/J.Jgo.2014.09.080 |
0.37 |
|
| 2013 |
Russell K, Amir E, Paterson A, Josse R, Addison C, Kuchuk I, Clemons M. Does estrogen play a role in response to adjuvant bone-targeted therapies? Journal of Bone Oncology. 2: 167-73. PMID 26909288 DOI: 10.1016/J.Jbo.2013.06.001 |
0.408 |
|
| 2013 |
McNamara MG, Walter T, Horgan AM, Amir E, Cleary S, McKeever EL, Min T, Wallace E, Hedley D, Krzyzanowska M, Moore M, Gallinger S, Greig P, Serra S, Dawson LA, et al. Outcome of Adjuvant Therapy in Biliary Tract Cancers. American Journal of Clinical Oncology. PMID 24572429 DOI: 10.1097/Coc.0B013E31829E19Fb |
0.38 |
|
| 2013 |
Manji A, Brana I, Amir E, Tomlinson G, Tannock IF, Bedard PL, Oza A, Siu LL, Razak AR. Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 4260-7. PMID 24127441 DOI: 10.1200/Jco.2012.47.4957 |
0.54 |
|
| 2013 |
Templeton AJ, Vera-Badillo FE, Wang L, Attalla M, De Gouveia P, Leibowitz-Amit R, Knox JJ, Moore M, Sridhar SS, Joshua AM, Pond GR, Amir E, Tannock IF. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 2972-7. PMID 24126362 DOI: 10.1093/Annonc/Mdt397 |
0.514 |
|
| 2013 |
Ocana A, Amir E, Vera-Badillo F, Seruga B, Tannock IF. Phase III trials of targeted anticancer therapies: redesigning the concept. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4931-40. PMID 23881926 DOI: 10.1158/1078-0432.Ccr-13-1222 |
0.504 |
|
| 2013 |
Al-Mubarak M, Sacher AG, Ocana A, Vera-Badillo F, Seruga B, Amir E. Fulvestrant for advanced breast cancer: a meta-analysis. Cancer Treatment Reviews. 39: 753-8. PMID 23764179 DOI: 10.1016/J.Ctrv.2013.03.004 |
0.441 |
|
| 2013 |
Bouganim N, Tsvetkova E, Clemons M, Amir E. Evolution of sites of recurrence after early breast cancer over the last 20 years: Implications for patient care and future research Breast Cancer Research and Treatment. 139: 603-606. PMID 23681402 DOI: 10.1007/S10549-013-2561-7 |
0.421 |
|
| 2013 |
Diaz-Padilla I, Romero N, Amir E, Matias-Guiu X, Vilar E, Muggia F, Garcia-Donas J. Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 88: 154-67. PMID 23562498 DOI: 10.1016/J.Critrevonc.2013.03.002 |
0.368 |
|
| 2013 |
Vera-Badillo FE, Al-Mubarak M, Templeton AJ, Amir E. Benefit and harms of new anti-cancer drugs. Current Oncology Reports. 15: 270-5. PMID 23435854 DOI: 10.1007/S11912-013-0303-Y |
0.398 |
|
| 2013 |
Vera-Badillo FE, Shapiro R, Ocana A, Amir E, Tannock IF. Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 1238-44. PMID 23303339 DOI: 10.1093/Annonc/Mds636 |
0.578 |
|
| 2013 |
Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, Amir E. HER3 overexpression and survival in solid tumors: a meta-analysis. Journal of the National Cancer Institute. 105: 266-73. PMID 23221996 DOI: 10.1093/Jnci/Djs501 |
0.323 |
|
| 2013 |
Amir E, Freedman O, Carlsson L, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M. Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer. American Journal of Clinical Oncology. 36: 436-42. PMID 22781385 DOI: 10.1097/Coc.0B013E3182568F7A |
0.479 |
|
| 2013 |
Ocaña A, Amir E, Seruga B, Martin M, Pandiella A. The evolving landscape of protein kinases in breast cancer: clinical implications. Cancer Treatment Reviews. 39: 68-76. PMID 22703833 DOI: 10.1016/J.Ctrv.2012.05.004 |
0.413 |
|
| 2013 |
Al-Mubarak M, Templeton A, Vera-Badillo F, Ocana A, Seruga B, Amir E. Abstract P6-06-12: Prognostic significance of pretreatment neutrophil/-lymphocyte ratio in breast cancer: A meta-analysis Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P6-06-12 |
0.434 |
|
| 2013 |
Abdel-Qadir H, Fischer H, Fu L, Amir E, Harvey P, Lee D, Rochon P, Anderson G. The Risk of Ischemic Heart Disease With Adjuvant Endocrine Therapy in Postmenopausal Women With Early Stage Breast Cancer Canadian Journal of Cardiology. 29: S348. DOI: 10.1016/J.Cjca.2013.07.594 |
0.38 |
|
| 2012 |
Mourskaia AA, Amir E, Dong Z, Tiedemann K, Cory S, Omeroglu A, Bertos N, Ouellet V, Clemons M, Scheffer GL, Park M, Hallett M, Komarova SV, Siegel PM. ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone. Breast Cancer Research : Bcr. 14: R149. PMID 23174366 DOI: 10.1186/Bcr3361 |
0.402 |
|
| 2012 |
Amir E, Bedard PL, Ocaña A, Seruga B. Benefits and harms of detecting clinically occult breast cancer. Journal of the National Cancer Institute. 104: 1542-7. PMID 22988040 DOI: 10.1093/Jnci/Djs394 |
0.417 |
|
| 2012 |
Templeton A, Ocaña A, Seruga B, Vera-Badillo F, Carlsson L, Bedard P, Amir E. Management of small HER2 overexpressing tumours. Breast Cancer Research and Treatment. 136: 289-93. PMID 22956007 DOI: 10.1007/S10549-012-2236-9 |
0.432 |
|
| 2012 |
Niraula S, Seruga B, Ocana A, Shao T, Goldstein R, Tannock IF, Amir E. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3012-9. PMID 22802313 DOI: 10.1200/Jco.2011.40.3824 |
0.494 |
|
| 2012 |
Fralick M, Hilton JF, Bouganim N, Clemons M, Amir E. Dual blockade of HER2 - twice as good or twice as toxic? Clinical Oncology (Royal College of Radiologists (Great Britain)). 24: 593-603. PMID 22748560 DOI: 10.1016/J.Clon.2012.05.009 |
0.401 |
|
| 2012 |
Seruga B, Pond GR, Hertz PC, Amir E, Ocana A, Tannock IF. Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 23: 2977-82. PMID 22734009 DOI: 10.1093/Annonc/Mds174 |
0.5 |
|
| 2012 |
Eng L, Azad AK, Habbous S, Pang V, Xu W, Maitland-van der Zee AH, Savas S, Mackay HJ, Amir E, Liu G. Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a systematic review and meta-analysis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4526-37. PMID 22733538 DOI: 10.1158/1078-0432.Ccr-12-1315 |
0.355 |
|
| 2012 |
Tabariès S, Dupuy F, Dong Z, Monast A, Annis MG, Spicer J, Ferri LE, Omeroglu A, Basik M, Amir E, Clemons M, Siegel PM. Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes. Molecular and Cellular Biology. 32: 2979-91. PMID 22645303 DOI: 10.1128/Mcb.00299-12 |
0.393 |
|
| 2012 |
Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 1934-40. PMID 22529261 DOI: 10.1200/Jco.2011.40.5381 |
0.396 |
|
| 2012 |
Amir E, Cecchini RS, Ganz PA, Costantino JP, Beddows S, Hood N, Goodwin PJ. 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. Breast Cancer Research and Treatment. 133: 1077-88. PMID 22415479 DOI: 10.1007/S10549-012-2012-X |
0.399 |
|
| 2012 |
Ocana A, Amir E, Yeung C, Seruga B, Tannock IF. How valid are claims for synergy in published clinical studies? Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 23: 2161-6. PMID 22314859 DOI: 10.1093/Annonc/Mdr608 |
0.477 |
|
| 2012 |
Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, Coleman RE, Freedman OC, Jordan LB, Thompson AM. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treatment Reviews. 38: 708-14. PMID 22178456 DOI: 10.1016/J.Ctrv.2011.11.006 |
0.421 |
|
| 2012 |
Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, Oldfield M, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer Journal of Clinical Oncology. 30: 587-592. PMID 22124102 DOI: 10.1200/Jco.2010.33.5232 |
0.499 |
|
| 2012 |
Amir E, Seruga B, Kwong R, Tannock IF, Ocaña A. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer? European Journal of Cancer (Oxford, England : 1990). 48: 385-8. PMID 22115991 DOI: 10.1016/J.Ejca.2011.10.028 |
0.499 |
|
| 2012 |
Vera Badillo FE, Shapiro R, Ocana A, Amir E, Tannock I. Bias in reporting of endpoints of efficacy and toxicity in randomized clinical trials (RCTs) for women with breast cancer (BC). Journal of Clinical Oncology. 30: 6043-6043. DOI: 10.1200/Jco.2012.30.15_Suppl.6043 |
0.52 |
|
| 2012 |
Seruga B, Zadnik V, Grasic Kuhar C, Marinko T, Zorman D, Cufer T, Zakotnik B, Ocana A, Amir E. Aromatase inhibitors and cardiac outcomes in women undergoing cardiac angiography after early breast cancer. Journal of Clinical Oncology. 30: 558-558. DOI: 10.1200/Jco.2012.30.15_Suppl.558 |
0.384 |
|
| 2012 |
Bouganim N, Vandermeer L, Kuchuk I, Dent S, Hopkins S, Song X, Robbins D, Spencer P, Mazzarello S, Hilton J, Amir E, Dranitsaris G, Addison C, Mallick R, Clemons M. Abstract P3-13-05: Evaluating efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal related events. TRIUMPH: A pragmatic multicentre trial. Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P3-13-05 |
0.37 |
|
| 2012 |
Sahebjam S, Diaz-Padilla I, Ocana A, Seruga B, Amir E. Abstract P2-10-23: Lymphovascular Invasion (LVI) and Overall Survival in Node-negative and Node-positive Breast Cancer Patients: A Meta-analysis. Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P2-10-23 |
0.383 |
|
| 2012 |
Addison C, Zhao H, Mazzarello S, Mallick R, Amir E, Tannock I, Clemons M. Abstract P2-05-12: Effects of de-escalated bisphosphonate therapy on bone turnover or metastasis markers and their correlation with risk of skeletal related events – A biomarker analysis in conjunction with the REFORM study. Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P2-05-12 |
0.462 |
|
| 2012 |
Manji A, Garcia IB, Amir E, Tannock IF, Bedard P, Oza AM, Siu L, Razak ARA. Evolution of Clinical Trial Design in Early Drug Development: The Use of Expansion Cohorts (ECS) in Phase I Cancer Trials (PITS) Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)33013-1 |
0.514 |
|
| 2012 |
Ocana A, Badillo FV, Seruga B, Pandiella A, Amir E. Meta-Analysis of HER3 Expression and Prognosis in Solid Tumors Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)32799-X |
0.384 |
|
| 2011 |
Bouganim N, Hilton JF, Vandermeer L, Hopkins S, Robbins D, Amir E, Dent S, Milano C, Freedman OC, Dent RA, Dranitsaris G, Clemons MJ. A multicenter study assessing 12-weekly intravenous bisphosphonate therapy in women with low-risk bone metastases from breast cancer: The TRIUMPH trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS242. PMID 28023584 DOI: 10.1200/Jco.2011.29.15_Suppl.Tps242 |
0.412 |
|
| 2011 |
Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, Khayat D, Boyle P, Autier P, Tannock IF, Fojo T, Siderov J, Williamson S, Camporesi S, McVie JG, et al. Delivering affordable cancer care in high-income countries. The Lancet. Oncology. 12: 933-80. PMID 21958503 DOI: 10.1016/S1470-2045(11)70141-3 |
0.507 |
|
| 2011 |
Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. Journal of the National Cancer Institute. 103: 1299-309. PMID 21743022 DOI: 10.1093/jnci/djr242 |
0.323 |
|
| 2011 |
Amir E, Seruga B, Martinez-Lopez J, Kwong R, Pandiella A, Tannock IF, Ocaña A. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2543-9. PMID 21606435 DOI: 10.1200/Jco.2011.35.2393 |
0.364 |
|
| 2011 |
Freedman O, Amir E, Zimmermann C, Clemons M. Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 19: 315-22. PMID 21203780 DOI: 10.1007/s00520-010-1069-5 |
0.309 |
|
| 2011 |
Dranitsaris G, Truter I, Lubbe MS, Amir E, Evans W. Advances in cancer therapeutics and patient access to new drugs. Pharmacoeconomics. 29: 213-24. PMID 21184619 DOI: 10.2165/11584210-000000000-00000 |
0.4 |
|
| 2011 |
Ocaña A, Amir E, Vera F, Eisenhauer EA, Tannock IF. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 254-6. PMID 21149670 DOI: 10.1200/Jco.2010.32.0275 |
0.489 |
|
| 2011 |
Saibil S, Fitzgerald B, Freedman OC, Amir E, Napolskikh J, Salvo N, Dranitsaris G, Clemons M. Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey. Current Oncology (Toronto, Ont.). 17: 42-7. PMID 20697513 DOI: 10.3747/CO.V17I4.562 |
0.325 |
|
| 2011 |
Florescu A, Amir E, Bouganim N, Clemons M. Immune therapy for breast cancer in 2010-hype or hope? Current Oncology. 18. DOI: 10.3747/Co.V18I1.623 |
0.41 |
|
| 2011 |
Niraula S, Amir E, Ocana A, Seruga B, Tannock I. The balance between benefits and harms of molecular targeted agents. Journal of Clinical Oncology. 29: 6030-6030. DOI: 10.1200/Jco.2011.29.15_Suppl.6030 |
0.465 |
|
| 2011 |
Seruga B, Horgan AM, Pond GR, Alibhai SMH, Amir E, De Wit R, Eisenberger MA, Tannock I. Tolerability and efficacy of chemotherapy in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. Journal of Clinical Oncology. 29: 4530-4530. DOI: 10.1200/Jco.2011.29.15_Suppl.4530 |
0.492 |
|
| 2011 |
Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer (BTC): A systematic review and meta-analysis. Journal of Clinical Oncology. 29: 4050-4050. DOI: 10.1200/Jco.2011.29.15_Suppl.4050 |
0.376 |
|
| 2011 |
Amir E, Cecchini RS, Ganz PA, Costantino JP, Beddows S, Hood N, Goodwin PJ. 25-hydroxy vitamin D (VitD) and associated variables as predictors of breast cancer (BC) risk and tamoxifen benefit in NSABP-P1. Journal of Clinical Oncology. 29: 1528-1528. DOI: 10.1200/Jco.2011.29.15_Suppl.1528 |
0.324 |
|
| 2011 |
Amir E, Freedman O, Carlsson L, Usmani T, Lee E, Dranitsaris G, Clemons M. P4-16-08: Pilot Randomized Trial of De-Escalated (q12 Weekly) Versus Standard (q3-4 Weekly) Intravenous Bisphosphonates in Women with Low-Risk Bone Metastases from Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P4-16-08 |
0.366 |
|
| 2011 |
Bouganim N, Clemons M, Amir E. P4-11-08: Changes in the Distribution of Loco-Regional and Distant Breast Cancer Recurrences over the Last 20 Years: Implications for Patient Care and Future Research. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P4-11-08 |
0.364 |
|
| 2011 |
Amir E, Carlsson L, Seruga B, Ocana A, Goodwin P. P4-10-02: A Meta-Analysis of the Association of Blood Levels of Vitamin-D and the Risk of Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P4-10-02 |
0.392 |
|
| 2011 |
Amir E, Seruga B, Ocaña A, Carlsson L, Bedard P. P2-12-07: Pooled Analysis of Outcomes of T1a/bN0, HER2−Amplified Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P2-12-07 |
0.415 |
|
| 2011 |
Bouganim N, Hilton J, Vandermeer L, Hopkins S, Spencer P, Robbins D, Amir E, Dent S, Milano C, Ooi D, Dranitsaris G, Clemons M. OT1-01-02: A Multicentre Study Assessing 12-Weekly Intravenous Bisphosphonate Therapy in Women with Low Risk Bone Metastases from Breast Cancer – The TRIUMPH Trial. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Ot1-01-02 |
0.426 |
|
| 2011 |
Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol N, Amir E, Khayat D, Boyle P, Tannock I, Fojo T. Delivering Affordable Cancer Care in High-income Countries: a Lancet Oncology Commission European Journal of Cancer. 47: 6. DOI: 10.1016/S0959-8049(11)70107-1 |
0.472 |
|
| 2010 |
Amir E, Freedman O, Allen L, Colgan T, Clemons M. Defining ovarian failure in amenorrheic young breast cancer patients. Breast (Edinburgh, Scotland). 19: 545-8. PMID 20615705 DOI: 10.1016/j.breast.2010.06.003 |
0.332 |
|
| 2010 |
Seruga B, Amir E. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Research and Treatment. 122: 609-17. PMID 20454926 DOI: 10.1007/s10549-010-0902-3 |
0.314 |
|
| 2010 |
Amir E, Freedman OC, Seruga B, Evans DG. Assessing women at high risk of breast cancer: a review of risk assessment models. Journal of the National Cancer Institute. 102: 680-91. PMID 20427433 DOI: 10.1093/Jnci/Djq088 |
0.364 |
|
| 2010 |
Amir E, Seruga B, Serrano R, Ocana A. Targeting DNA repair in breast cancer: a clinical and translational update. Cancer Treatment Reviews. 36: 557-65. PMID 20385443 DOI: 10.1016/J.Ctrv.2010.03.006 |
0.36 |
|
| 2010 |
Amir E, Ocaña A, Seruga B, Josse R, Clemons M. Medical oncology: Zoledronic acid for breast cancer therapy-induced bone loss. Nature Reviews. Clinical Oncology. 7: 187-8. PMID 20354540 DOI: 10.1038/Nrclinonc.2010.19 |
0.383 |
|
| 2010 |
Amir E, Ocana A, Freedman O, Clemons M, Seruga B. Chemotherapy: dose-dense treatment for triple-negative breast cancer. Nature Reviews. Clinical Oncology. 7: 79-80. PMID 20118978 DOI: 10.1038/Nrclinonc.2009.231 |
0.41 |
|
| 2010 |
Amir E, Ocaña A, Seruga B, Freedman O, Clemons M. Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer. Cancer Treatment Reviews. 36: 410-5. PMID 20100635 DOI: 10.1016/J.Ctrv.2009.12.012 |
0.412 |
|
| 2010 |
Amir E, Simmons CE, Freedman OC, Dranitsaris G, Cole DE, Vieth R, Ooi WS, Clemons M. A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases. Cancer. 116: 284-91. PMID 19918922 DOI: 10.1002/Cncr.24749 |
0.322 |
|
| 2010 |
Freedman OC, Amir E, Hanna W, Kahn H, O'Malley F, Dranitsaris G, Cole DE, Verma S, Folkerd E, Dowsett M, Clemons M. A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer. Breast Cancer Research and Treatment. 119: 155-61. PMID 19731013 DOI: 10.1007/S10549-009-0523-X |
0.427 |
|
| 2010 |
Bouganim N, Amir E, Clemons M. Bonus 5: 5th annual bone and the oncologist new updates Current Oncology. 17: 113-118. DOI: 10.3747/Co.V17I4.691 |
0.334 |
|
| 2010 |
Simmons CE, Amir E, Lee E, Hogeveen S, Dent RA, Goodwin PJ, Clemons M. Suppression of bone turnover following treatment with zoledronic acid in patients wtih metastatic breast cancer: Duration of effect—The SuBDuE study. Journal of Clinical Oncology. 28: TPS121-TPS121. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps121 |
0.3 |
|
| 2010 |
Amir E, Clemons M, Freedman OC, Miller N, Coleman RE, Purdie C, Jordan L, Quinlan P, Thompson AM. Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies. Journal of Clinical Oncology. 28: 1007-1007. DOI: 10.1200/Jco.2010.28.15_Suppl.1007 |
0.378 |
|
| 2010 |
Amir E, Ocaña A, Niraula S, Carlsson L, Seruga B. Abstract S2-7: Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-S2-7 |
0.431 |
|
| 2010 |
Amir E, Miller N, Geddie W, Maung H, Freedman O, Oldfield M, Napolskikh J, Kassam F, Simmons C, Clemons M. Abstract PD10-05: Do the Results of Metastatic Breast Tumour Biopsies Affect Patient Survival Outcomes? Results from a Large Prospective Trial Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-Pd10-05 |
0.408 |
|
| 2010 |
Amir E, Ouellet V, Mourskaia A, Tiedemann K, Fong J, Tran-Tanh D, Clemons M, Perbal B, Komorova S, Siegel P. Abstract P6-07-01: CCN3 Impairs Osteoblasts and Stimulates Osteoclast Differentiation To Favor Breast Cancer Metastasis to Bone Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P6-07-01 |
0.372 |
|
| 2010 |
Freedman O, Amir E, Cheung A, Hu H, Lee E, Dranitsaris G, Clemons M. Abstract P1-13-08: A Cross-Sectional Study Evaluating Bone Quantity and Quality in Women with Bone Metastases from Breast Cancer Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P1-13-08 |
0.329 |
|
| 2009 |
Amir E, Freedman OC, Dranitsaris G, Napolskikh J, Chia S, Petrella T, Dent S, Kumar R, Fralick M, Clemons M. Developing a prediction model for benefit from fulvestrant in heavily pretreated metastatic breast cancer (MBC) patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1041. PMID 27961124 DOI: 10.1200/Jco.2009.27.15_Suppl.1041 |
0.401 |
|
| 2009 |
Broom RJ, Amir E, Cawthorn T, Freedman O, Gianfelice D, Barth D, Galica J, Wang D, Done SJ, Clemons M. Gene expression differences between disseminated tumor cells and tumor cells from overt bone metastases in patients with metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1040. PMID 27961118 DOI: 10.1200/Jco.2009.27.15_Suppl.1040 |
0.314 |
|
| 2009 |
Seruga B, Amir E, Tannock I. Treatment of lung cancer. The New England Journal of Medicine. 361: 2485; author reply 2. PMID 20050212 DOI: 10.1056/NEJMc0909634 |
0.399 |
|
| 2009 |
Amir E, Seruga B, Freedman O, Clemons M. Amenorrhoea, menopause, and endocrine therapy for breast cancer. Bmj (Clinical Research Ed.). 339: b4261. PMID 19959583 DOI: 10.1136/Bmj.B4261 |
0.413 |
|
| 2009 |
Amir E, Tannock IF. Prostate cancer: Androgen deprivation therapy and bone loss. Nature Reviews. Urology. 6: 642-4. PMID 19956194 DOI: 10.1038/Nrurol.2009.218 |
0.471 |
|
| 2009 |
Amir E, Clemons M. Should a biopsy be recommended to confirm metastatic disease in women with breast cancer? The Lancet. Oncology. 10: 933-5. PMID 19796747 DOI: 10.1016/S1470-2045(09)70295-5 |
0.39 |
|
| 2009 |
Ocaña A, Amir E. Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions. Cancer Treatment Reviews. 35: 685-91. PMID 19733440 DOI: 10.1016/J.Ctrv.2009.08.001 |
0.398 |
|
| 2009 |
Cawthorn TR, Amir E, Broom R, Freedman O, Gianfelice D, Barth D, Wang D, Holen I, Done SJ, Clemons M. Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples. Clinical & Experimental Metastasis. 26: 935-43. PMID 19697143 DOI: 10.1007/S10585-009-9284-5 |
0.321 |
|
| 2009 |
Freedman O, Amir E, Dranitsaris G, Napolskikh J, Kumar R, Fralick M, Chia S, Petrella T, Dent S, Tonkin K, Ahmad I, Rayson D, Clemons M. Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients. Breast Cancer Research and Treatment. 118: 377-83. PMID 19551499 DOI: 10.1007/S10549-009-0452-8 |
0.415 |
|
| 2009 |
Freedman OC, Amir E, Clemons MJ. Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction? Critical Reviews in Oncology/Hematology. 72: 56-64. PMID 19307138 DOI: 10.1016/J.Critrevonc.2009.03.001 |
0.46 |
|
| 2009 |
Amir E, Whyne C, Freedman OC, Fralick M, Kumar R, Hardisty M, Clemons M. Radiological changes following second-line zoledronic acid treatment in breast cancer patients with bone metastases Clinical and Experimental Metastasis. 26: 479-484. PMID 19266291 DOI: 10.1007/S10585-009-9247-X |
0.317 |
|
| 2009 |
Amir E, Seruga B, Freedman O, Tannock I. Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1919; author reply 1. PMID 19255302 DOI: 10.1200/Jco.2008.21.2951 |
0.544 |
|
| 2009 |
Freedman O, Amir E, Dranitsaris G, Dowsett M, Cole D, Kahn H, O'Malley F, Verma S, Clemons M. A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and nonsteroidal (anastrozole) aromatase inhibitors on biomarkers in postmenopausal women with hormone receptor-positive locally advanced breast cancer Breast Cancer Research. 11. DOI: 10.1186/Bcr2316 |
0.463 |
|
| 2009 |
Amir E, Freedman O, Simmons C, Miller N, Geddie W, DeBorja A, Maung H, Gianfelice D, Murphy K, Clemons M. Biopsy confirmation of metastatic breast cancer: interim results of a prospective biopsy study Breast Cancer Research. 11. DOI: 10.1186/Bcr2314 |
0.411 |
|
| 2009 |
Amir E, Freedman O, Chia S, Petrella T, Dent S, Tonkin K, Ahmad I, Rayson D, Dranitsaris G, Clemons M. Developing a prediction model for benefit from fulvestrant in heavily pretreated metastatic breast cancer patients Breast Cancer Research. 11. DOI: 10.1186/Bcr2312 |
0.433 |
|
| 2009 |
Amir E, Broom R, Freedman O, Ooi W, Done S, Gianfelice D, Barth D, Kahn H, Clemons M. Discordance between hormone receptor profile of primary breast cancer and metastatic bone disease: should bone marrow biopsy be considered a standard of care? Breast Cancer Research. 11. DOI: 10.1186/Bcr2310 |
0.341 |
|
| 2009 |
Amir E, Freedman O, Simmons C, Miller N, Geddie W, Dranitsaris G, Maung H, Napolskikh J, Lax M, Clemons M. Biopsy Confirmation of Metastatic Disease in Breast Cancer: Results from a Large Prospective Study. Cancer Research. 69: 2023-2023. DOI: 10.1158/0008-5472.Sabcs-09-2023 |
0.37 |
|
| 2009 |
Freedman O, Amir E, Dranitsaris G, Dowsett M, Cole D, Hanna W, O'Malley F, Folkerd E, Verma S, Clemons M. 5027 A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and non-steroidal (anastrozole) aromatase inhibitors on biomarkers in post-menopausal women with hormone receptor positive locally advanced breast cancer (LABC) European Journal of Cancer Supplements. 7: 269. DOI: 10.1016/S1359-6349(09)70919-X |
0.409 |
|
| 2008 |
Amir E, Ooi WS, Simmons C, Kahn H, Christakis M, Popovic S, Kalina M, Chesney A, Singh G, Clemons M. Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies. Clinical Oncology (Royal College of Radiologists (Great Britain)). 20: 763-8. PMID 18824337 DOI: 10.1016/J.Clon.2008.08.005 |
0.35 |
|
| 2008 |
Al-Husaini H, Amir E, Fitzgerald B, Wright F, Dent R, Fralick J, Clemons M. Prevalence of overt metastases in locally advanced breast cancer. Clinical Oncology (Royal College of Radiologists (Great Britain)). 20: 340-4. PMID 18420394 DOI: 10.1016/j.clon.2008.03.006 |
0.302 |
|
| Show low-probability matches. |